1. Cancer Biology
  2. Developmental Biology

A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion

  1. Katarina Valoskova
  2. Julia Biebl
  3. Marko Roblek
  4. Shamsi Emtenani
  5. Attila Gyoergy
  6. Michaela Misova
  7. Aparna Ratheesh
  8. Patricia Reis-Rodrigues
  9. Kateryna Shkarina
  10. Ida Signe Bohse Larsen
  11. Sergey Y Vakhrushev
  12. Henrik Clausen
  13. Daria E Siekhaus  Is a corresponding author
  1. Institute of Science and Technology Austria, Austria
  2. University of Warwick, United Kingdom
  3. University of Copenhagen, Denmark
https://doi.org/10.7554/eLife.41801
Share this article
Cite this article
  1. Katarina Valoskova
  2. Julia Biebl
  3. Marko Roblek
  4. Shamsi Emtenani
  5. Attila Gyoergy
  6. Michaela Misova
  7. Aparna Ratheesh
  8. Patricia Reis-Rodrigues
  9. Kateryna Shkarina
  10. Ida Signe Bohse Larsen
  11. Sergey Y Vakhrushev
  12. Henrik Clausen
  13. Daria E Siekhaus
(2019)
A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion
eLife 8:e41801.
https://doi.org/10.7554/eLife.41801
  2. Download BibTeX
  3. Download .RIS

Abstract

Aberrant display of the truncated core1 O-glycan T-antigen is a common feature of human cancer cells that correlates with metastasis. Here we show that T-antigen in Drosophila melanogaster macrophages is involved in their developmentally programmed tissue invasion. Higher macrophage T-antigen levels require an atypical major facilitator superfamily (MFS) member that we named Minerva which enables macrophage dissemination and invasion. We characterize for the first time the T and Tn glycoform O-glycoproteome of the Drosophila melanogaster embryo, and determine that Minerva increases the presence of T-antigen on proteins in pathways previously linked to cancer, most strongly on the sulfhydryl oxidase Qsox1 which we show is required for macrophage tissue entry. Minerva’s vertebrate ortholog, MFSD1, rescues the minerva mutant’s migration and T-antigen glycosylation defects. We thus identify a key conserved regulator that orchestrates O-glycosylation on a protein subset to activate a program governing migration steps important for both development and cancer metastasis.

https://doi.org/10.7554/eLife.41801.001

eLife digest

Proteins, the workhorses of the body, participate in virtually every single process in a cell. Different types of molecules, such as sugars, can be added onto a protein to change its role or location, but this process may also play a role in cancer. Indeed, tumor cells that contain certain sugar modifications are more likely to be able to spread through the body. For example, a specific combination of sugars called T antigen is rarely present in healthy adult cells; yet, it is commonly found in cancer cells that leave the tumor where they were born and invade another tissue to form a new tumor. However, it is not clear whether T antigen actively helps this process inside the body, or is simply present during it.

To answer this question, Valosková, Biebl et al. used genetic and biochemistry tools to study developing fruit fly embryos, where certain immune cells carry T antigen on their proteins. Like invading cancer cells, these immune cells can get inside tissues during development. The experiments revealed that a protein called Minerva helps attach T antigen onto proteins. When embryos were engineered to contain less Minerva, the amount of T antigen in the immune cells dropped, and the cells could not easily make their way into tissues anymore. When the mouse version of Minerva was then added to the embryos, the immune cells of the fruit flies had higher T antigen levels on their proteins and could invade tissues again.

Some of the proteins targeted by Minerva were known to be involved in cancer, but not all of them. Future experiments will investigate which role the human version of Minerva plays in cancer cells that get inside new tissues, and if it could help us predict whether a cancer is likely to spread.

https://doi.org/10.7554/eLife.41801.002

Introduction

The set of proteins expressed by a cell defines much of its potential capacities. However, a diverse set of modifications can occur after the protein is produced to alter its function and thus determine the cell’s final behavior. One of the most frequent and variable of such alterations is glycosylation, in which sugars are added onto the oxygen (O) of a serine or threonine or onto the nitrogen (N) of an asparagine (Kornfeld and Kornfeld, 1985; Marshall, 1972; Ohtsubo and Marth, 2006). O-linked addition can occur on cytoplasmic and nuclear proteins in eukaryotes (Comer and Hart, 2000; Hart et al., 2011), but the most extensive N- and O- linked glycosylation occurs during the transit of a protein through the secretory pathway. A series of sugar molecules are added starting in the endoplasmic reticulum (ER) or cis-Golgi and continuing to be incorporated and removed until passage through the trans Golgi network is complete (Aebi, 2013; Stanley et al., 2009). N-linked glycosylation is initiated in the ER at consensus NxS/T X≠P site, whereas the most common GalNAc-type O-linked glycosylation is initiated in the early Golgi and glycosites display no clear sequence motifs, apart from a prevalence of neighboring prolines (Bennett et al., 2012; Thanka Christlet and Veluraja, 2001). Glycosylation can affect protein folding, stability and localization as well as serve specific roles in fine-tuning protein processing and functions such as protein adhesion and signaling (Goth et al., 2018; Varki, 2017). The basic process by which such glycosylation occurs has been well studied. However our understanding of how specific glycan structures participate in modulating particular cellular functions is still at its beginning.

The need to understand the regulation of O-glycosylation is particularly relevant for cancer (Fu et al., 2016; Häuselmann and Borsig, 2014). The truncated O-glycans called T and Tn antigen are not normally found on most mature human cells (Cao et al., 1996) but up to 95% of cells from many cancer types display these at high levels (Boland et al., 1982; Cao et al., 1996; Howard and Taylor, 1980; Limas and Lange, 1986; Orntoft et al., 1985; Springer, 1984; Springer et al., 1975). The T O-glycan structure (Galβ1-3GalNAcα1-O-Ser/Thr) is synthesized by the large family of polypeptide GalNAc-transferases (GalNAc-Ts) that initiate protein O-glycosylation by adding GalNAc to form Tn antigen and the core1 synthase C1GalT1 that adds Gal to the initial GalNAc residues (Tian and Ten Hagen, 2009) to form T antigen (Figure 1A). The human C1GalT1 synthase requires a dedicated chaperone, COSMC, for folding and ER exit (Ju and Cummings, 2005). In adult humans these O-glycans are normally capped by sialic acids and/or elongated and branched into complex structures (Tarp and Clausen, 2008). However, in cancer this elongation and branching is reduced or absent and the appearance of these truncated T and Tn O-glycans correlates positively with cancer aggressiveness and negatively with long-term prognoses for many cancers in patients (Baldus et al., 2000; Carrasco et al., 2013; Ferguson et al., 2014; MacLean and Longenecker, 1991; Schindlbeck et al., 2005; Springer, 1997; Springer, 1989; Summers et al., 1983; Yu et al., 2007). The molecular basis for the enhanced appearance of T antigen in cancers is not clear (Chia et al., 2016), although higher Golgi pH in cancer cells correlates with increases in T antigen (Kellokumpu et al., 2002). Interestingly, T antigen is also observed as a transient fetal modification (Barr et al., 1989) and cancer cells frequently recapitulate processes that happened earlier in development (Cofre and Abdelhay, 2017; Pierce, 1974). Identifying new mechanisms that regulate T antigen modifications developmentally has the potential to lead to insights into cancer biology.

Figure 1 with 1 supplement see all
Download asset Open asset
T antigen is enriched on Drosophila macrophages prior to and during their invasion of the extended germband.

(A) Schematic of T antigen modification of serine (S) and threonine (T) on proteins within the Golgi lumen, through successive addition of GalNAc (yellow) by GalNAcTs and Gal (blue) by C1GalTs. Ugalt transports Gal into the Golgi. Glycosylation is shown at a much larger scale than the protein. (B) Schematic of an early Stage 12 embryo and a magnification of macrophages (red) entering between the germband ectoderm (dark grey), and mesoderm (light grey). (C) Schematic showing macrophages (red) disseminating from the head mesoderm in Stage 9. By Stage 10, they migrate towards the extended germband, the dorsal vessel and along the ventral nerve cord (vnc). At late Stage 11 germband invasion (arrow) begins and continues during germband retraction. Arrowhead highlights migration along the vnc in late Stage 12. (D) Table summarizing a screen of glycosylation-binding lectins for staining on macrophages invading the germband in late Stage 11 embryos. The listed binding preferences are abbreviated summaries of the specificities defined with mammalian glycans or simple saccharides which may have only incomplete relevance to insect glycomes. Enrichment was seen for PNA which recognizes T antigen and UEA-I which can recognize fucose. (E) Quantification of T antigen fluorescence intensities on wild type embryos shows upregulation on macrophages between Stage 9/10 and Stage 11/12. Arbitrary units (au) normalized to one for Stage 11. p<0.0001. (F–H) Confocal images of fixed lateral wild type embryos from (F) Stage 9 and (G–H) early Stage 12 with T antigen visualized by antibody staining (green) and macrophages by srpHemo-3xmCherry expression (red). Schematics at left with black boxes showing the imaged regions. (I) Quantification of control shows T antigen enrichment on macrophages when normalized to whole embryo. RNAi in macrophages against C1GalTA by srpHemo(macrophage)>C1 GalTA RNAi vdrc2826 significantly decreases this T antigen staining (n = 8 embryos, p=0.011). (J) Representative confocal images of Stage 12 embryos from control and the aforementioned C1GalTA RNAi. Macrophages marked with cytoplasmic GFP (red) and nuclear RFP (green). (K,L) Quantification of macrophages in the germband in Stage 12 embryos for (K) control and two independent RNAis against C1GalTA (vdrc110406 or vdrc2826) expressed in macrophages by the srpHemo-Gal4 driver (n = 21–31 embryos, p<0.0001 and 0.017) or (L) in control and the C1GalTA[2.1] excision mutant (n = 23–24, p=0.0006). Macrophages labeled with srpHemo-H2A::3xmCherry. The RNAis and the mutant significantly decreased the macrophage number, arguing that T antigen is required in macrophages for germband entry. (M) Quantification of germband macrophages in early Stage 12 embryos in control and GlcAT-PMI05251 embryos shows no defect in macrophage invasion in the mutant (n = 17–20, p=0.962). (E) analyzed by Kruskal-Wallis test I, K-M analyzed by Student’s t-test. ns = p > 0.05, *p<0.05; **p<0.01; ***p<0.001. Scale bars represent 10 μm in F–H, and 50 μm in J. See also Figure 1—figure supplement 1.

https://doi.org/10.7554/eLife.41801.003
Figure 1—source data 1

Source data on the quantification of T antigen levels shown in Figure 1E and Figure 1I, the number of macrophages in the germband shown in Figure 1K–M, and the number on the yolk shown in Figure 1—figure supplement 1N–O,Q and on the vnc (Figure 1—figure supplement 1P).

https://doi.org/10.7554/eLife.41801.005

Drosophila as a classic genetic model system is an excellent organism in which to investigate these questions. Drosophila displays T antigen as the predominant form of GalNAc-, or mucin-type, O-glycosylation in the embryo with 18% of the T glycans being further elaborated, predominantly by the addition of GlcA (Aoki et al., 2008). As in vertebrates, the GalNAc-T isoenzymes directing the initial step of GalNAc addition to serines and threonines are numerous in Drosophila, with several already known to display conserved substrate specificity in vitro with their vertebrate orthologs (Müller et al., 2005; Schwientek et al., 2002; Ten Hagen et al., 2003). The Drosophila GalNAc-Ts affect extracellular matrix (ECM) secretion, gut acidification and the formation of the respiratory system (Tian and Ten Hagen, 2006; Tran et al., 2012; Zhang et al., 2010). In flies the main enzyme adding Gal to form T antigen is C1GalTA (Müller et al., 2005) whose absence causes defects in ventral nerve cord (vnc) condensation during Stage 17, hematopoetic stem cell maintenance, and neuromuscular junction formation (Fuwa et al., 2015; Itoh et al., 2016; Lin et al., 2008; Yoshida et al., 2008). While orthologous to the vertebrate Core1 synthases, the Drosophila C1GALTs differ in not requiring a specific chaperone (Müller et al., 2005). Most interestingly, T antigen is found on embryonic macrophages (Yoshida et al., 2008), a cell type which can penetrate into tissues in a manner akin to metastatic cancer (Ratheesh et al., 2018; Siekhaus et al., 2010). Macrophage invasion of the germband (Figure 1B, arrow in Figure 1C) occurs between the closely apposed ectoderm and mesoderm (Ratheesh et al., 2018; Siekhaus et al., 2010) from late Stage 11 through Stage 12. This invasion occurs as part of the dispersal of macrophages throughout the embryo (Figure 1C) along other routes that are mostly noninvasive, such as along the inner ventral nerve cord (vnc) (arrowhead in Figure 1C) (Campos-Ortega and Hartenstein, 1997; Evans et al., 2010). Given these potentially related but previously unconsolidated observations, we sought to determine the relationship between the appearance of T antigen and macrophage invasion and to use the genetic power of Drosophila to find new pathways by which this glycophenotype is regulated.

Results

T antigen is enriched and required in invading macrophages in Drosophila embryos

To identify glycan structures present on fly embryonic macrophages during invasion we performed a screen examining FITC-labelled lectins (see Materials and methods for abbreviations). Only two lectins had higher staining on macrophages than on surrounding tissues (labeled enriched): PNA, which primarily binds to the core1 T O-glycan, and UEA-I, which can recognize Fucα1-2Galβ1-4GlcNAc(Molin et al., 1986; Natchiar et al., 2007) (Figure 1D, Figure 1—figure supplement 1A–B). Both glycans are associated with the invasive migration of mammalian cancer cells (Agrawal et al., 2017; Hung et al., 2014). SBA, WGA, GS-II, GS-I, ConA, MPA and BPA bound at similar or lower levels on Drosophila macrophages compared to flanking tissues (Figure 1D, Figure 1—figure supplement 1C–I). We saw no staining with the sialic acid-recognizing lectin LPA, and none with DBA and HPA, that both recognize α-GalNAc (Piller et al., 1990) (Figure 1D, Figure 1—figure supplement 1J–L). Thus PNA and UEA-I display enriched macrophage binding during their embryonic invasive migration.

To confirm T antigen as the source of the upregulated PNA signal in embryonic macrophages during invasion and to characterize its temporal and spatial enrichment, we used a monoclonal antibody (mAb 3C9) to the T O-glycan structure (Steentoft et al., 2011). Through Stage 10, macrophages displayed very little T antigen staining, similar to other tissues (Figure 1E,F). However, at late Stage 11 (Figure 1—figure supplement 1A) and early Stage 12, when macrophages start to invade the extended germband, T antigen staining began to be enriched on macrophages moving towards and into the germband (Figure 1E–H). Our results are consistent with findings showing T antigen expression in a macrophage-like pattern in late Stage 12 embryos, and on a subset of macrophages at Stage 16 (Yoshida et al., 2008). We knocked down the core1 synthase C1GalTA required for the final step of T antigen synthesis (Figure 1A) (Lin et al., 2008; Müller et al., 2005) using RNAi expression only in macrophages and observed strongly reduced staining (Figure 1I, Figure 1—figure supplement 1M). We conclude that the antibody staining is the result of T antigen produced by macrophages themselves.

To determine if these T O-glycans on macrophages are important for facilitating their germband invasion, we knocked down C1GalTA in macrophages with the RNAi line utilized above as well as one other and used the P element excision allele C1GalTA[2.1] which removes conserved sequence motifs required for activity (Lin et al., 2008). We visualized macrophages through specific expression of fluorescent markers and observed a 25 and a 33% decrease in their number in the germband for the RNAis (Figure 1J,K), and a 44% decrease in the C1GalTA[2.1] mutant (Figure 1L). When we counted the number of macrophages sitting on the yolk next to the germband in the strongest RNAi we observed an increase (Figure 1—figure supplement 1N) that we also observed in the C1GalT mutant (Figure 1—figure supplement 1O). The sum of the macrophages in the yolk and germband is the same in the control, RNAi knockdown (control 136.5 ± 6.4, RNAi 142.3 ± 6.6, p=0.7) and mutant (control 138.5 ± 4.9, mutant, 142.3 ± 7.4, p=0.87) arguing that macrophages in which C1GalTA levels are reduced cannot enter the germband but are retained on the yolk. We observed no effect on the migration of macrophages on the vnc, a route that does not require tissue invasion (Figure 1—figure supplement 1P) (Campos-Ortega and Hartenstein, 1997; Evans et al., 2010). 18% of T antigen in the embryo has been found to be further modified, predominantly by glucuronic acid (GlcA) (Aoki et al., 2008). Of the three GlcA transferases found in Drosophila only GlcAT-P is robustly capable of adding GlcA onto the T O-glycan structure in cells (Breloy et al., 2016; Itoh et al., 2018; Kim et al., 2003). To examine if the specific defect in germband invasion that we observed by blocking the formation of T antigen is due to the need for a further elaboration by GlcA, we utilized a lethal MI{MIC} transposon insertion mutant in the GlcAT-P gene. We observed no change in the numbers of macrophages within the germband in the GlcAT-PMI05251 mutant (Figure 1M) and a 20% increase in the number of macrophages on the yolk (Figure 1—figure supplement 1Q). Therefore, our results strongly suggest that the T antigen we observe being upregulated in macrophages as they move towards and into the germband is itself needed for efficient tissue invasion.

An atypical MFS member acts in macrophages to increase T antigen levels

We sought to determine which proteins could temporally regulate the increase in the appearance of T O-glycans in invading macrophages. We first considered proteins required for synthesizing the core1 structure, namely the T synthase, C1GalTA, and the UDP-Gal sugar transporter, Ugalt (Aumiller and Jarvis, 2002) (Figure 1A). However, q-PCR analysis of FACS sorted macrophages from Stage 9–10, Stage 12, and Stage 13–17 show that though both are enriched in macrophages, neither is transcriptionally upregulated before or during Stage 12 (Figure 2A,B). We therefore examined the Bloomington Drosophila Genome Project (BDGP) in situ database looking for predicted sugar binding proteins expressed in macrophages with similar timing to the observed T antigen increase (Tomancak et al., 2007; Tomancak et al., 2002). We identified CG8602, a predicted member of the Major Facilitator Superfamily (MFS), a protein group defined by shared structural features, whose members are known to transport a diverse set of molecules across membranes (Yan, 2015). CG8602 contains regions of homology to known sugar responsive proteins and predicted sugar or neurotransmitter transporters (Figure 2C) and in a phylogenetic analysis is on a branch neighboring the SLC29 group shown to be involved in nucleoside transport (Baldwin et al., 2004; Perland et al., 2017). BDGP in situ hybridizations (Tomancak et al., 2007; Tomancak et al., 2002) (http://insitu.fruitfly.org/cgi-bin/ex/report.pl?ftype=10&ftext=FBgn0035763) indicate that CG8602 RNA is maternally deposited, with expression throughout the embryo through Stage 4 after which its levels decrease, with weak ubiquitous expression continuing through Stage 9–10. This is followed by strong enrichment in macrophages from Stage 11–12, with apparently equivalent levels of expression in macrophages entering the germband as in those migrating along other routes such as the ventral nerve cord. We confirmed this by q-PCR analysis of FACS sorted macrophages, which detected seven-fold higher levels of CG8602 RNA in macrophages than in the rest of the embryo by Stage 9–10 and 12-fold by Stage 12 (Figure 2D). These data show that RNA expression of CG8602, an MFS protein with homology to sugar transporters, increases in macrophages preceding and during the period of invasion.

Figure 2 with 1 supplement see all
Download asset Open asset
An atypical MFS family member, CG8602, located in the Golgi and endosomes, is required for T antigen enrichment on invading macrophages.

(A,B) qPCR quantification (2-ΔCt) of RNA levels in mCherry+ macrophages FACS sorted from srpHemo-3xmCherry wild type embryos reveals no significant change in the expression of (A) the C1GalTA galactose transferase or (B) the Ugalt Gal transporter during Stage 9–17 (n = 7 biological replicates, three independent FACS sorts). (C) Schematic made with Protter (Omasits et al., 2014) showing the predicted 12 transmembrane domains of CG8602. Blue lines indicate regions displaying higher than 20% identity to the correspondingly numbered Drosophila protein indicated below, along with the homologous protein’s predicted or determined function. (D) Quantification by qPCR of CG8602 RNA levels in FACS sorted mCherry+ macrophages compared to other mCherry- cells obtained from srpHemo-3xmCherry wild type embryos at Stage 9–10, Stage 12 and Stage 13–17. CG8602 macrophage expression peaks at Stage 12, during macrophage germband entry (n = 3–7 biological replicates, four independent FACS sorts, p=0.036). (E) qPCR quantification in FACS sorted srpHemo-3xmCherry labeled macrophages from control and CG8602EP3102 mutant Stage 12 embryos shows an extremely strong decrease in CG8602 RNA expression in the P element insertion mutant used in this study (n = 7 biological replicates, three independent FACS sorts, p=0.0024). (F) Confocal images of Stage 12 control and CG8602EP3102 mutant embryos with macrophages (red) visualized by srpHemo-mCherry expression and T antigen by antibody staining (green). Schematic at left depicts macrophages (red) entering the germband. Black box indicates the region next to the germband imaged at right. We observe decreased T antigen staining on macrophages in the CG8602EP3102 mutant compared to the control. (G) qPCR quantification (2-ΔCt) of C1GalTA and Ugalt RNA levels in FACS sorted macrophages from Stage 12 embryos from control and CG8602EP3102 mutant embryos shows no significant change in expression of the Gal transferase, or the Gal and GalNAc transporter in the mutant compared to the control (n = 7 biological replicates, three independent FACS sorts). (H) Quantitation using Fiji of the colocalization of transfected MT-CG8602::FLAG::HA in fixed S2R+ cells with markers for the ER (Cnx99a), the Golgi (Golgin 84, Golgin 245, and GMAP), the early endosome (Hrs), the late endosome (Rab7), and live S2R+ cells transfected with srp-CG8602::3xmCherry with dyes that mark the lysosome (Lysotracker) and the nucleus (DAPI). Representative images are shown in Figure 2—figure supplement 1 B-J. n = 24, 23, 23, 17, 6, 22, 6 and 13 cells analyzed per respective marker. (I) Macrophages near the germband extracted from srpHemo >CG8602 HA Stage 11/12 embryos show partial colocalization of the HA antibody labeling CG8602 (red) and a Golgin 84 or Hrs antibody marking the Golgi or endosome respectively (green). Nucleus is stained by DAPI (blue). For all qPCR experiments values are normalized to expression of a housekeeping gene RpL32. Scale bars are 5 μm in F, 3 μm in I. Significance was assessed by Kruskal-Wallis test in A, B, One way Anova in D and Student’s t-test in E, G. ns = p > 0.05, *p<0.05, ***p<0.001. See also Figure 2—figure supplement 1.

https://doi.org/10.7554/eLife.41801.006
Figure 2—source data 1

Source data on the quantification of C1GalTA, Ugalt, and CG8602 expression in macrophages by qPCR (shown in Figure 2A–B,D–E,G) and the Pearson’s coefficient for CG8602 colocalization with different markers (Figure 2H).

https://doi.org/10.7554/eLife.41801.008

To determine if CG8602 could affect T antigen levels, we examined a viable P-element insertion mutant in the 5’UTR, CG8602EP3102 (Figure 2—figure supplement 1A). This insertion displays strongly reduced CG8602 expression in FACS-sorted macrophages to 15% of wild type levels, as assessed by q-PCR (Figure 2E). We also created an excision allele, ∆33, removing the 5’UTR flanking the P-element, the start methionine, and 914 bp of the ORF (Figure 2—figure supplement 1A). This is a lethal allele, and the line carrying it over a balancer is very weak; exceedingly few embryos are laid and the embryos homozygous for the mutation do not develop past Stage 12. Therefore, we did not continue experiments with this allele, and instead utilized the insertion mutant. This CG8602EP3102 P-element mutant displays decreased T antigen staining on macrophages moving toward and entering the germband (Figure 2F) in Stage 11 through late Stage 12. q-PCR analysis on FACS sorted macrophages show that the reduction in T antigen levels in the mutant is not caused by changes in the RNA levels of the T synthase C1GalTA or the Ugalt Gal and GalNAc transporter (Aumiller and Jarvis, 2002; Segawa et al., 2002) (Figure 2G). These results argue that CG8602 is required for enriched T antigen levels on macrophages.

To assess if CG8602 could directly regulate T antigen addition, we examined if it is found in the Golgi where O-glycosylation is initiated. We first utilized the macrophage-like S2R+ cell line, transfecting a FLAG::HA or 3xmCherry labeled form of CG8602 under the control of srpHemo or the copper inducible MT promoter. We detected significant colocalization with markers for the cis-Golgi marker GMAP, the Trans Golgi Network marker Golgin 245 and the endosome markers Rab7, Rab11 and Hrs (Riedel et al., 2016) (Figure 2H, Figure 2—figure supplement 1C–G). We detected no colocalization with markers for the nucleus, ER, peroxisomes, mitochondria or lysosomes (Figure 2H, Figure 2—figure supplement 1B,H–J). We confirmed the presence of CG8602 in the Golgi and endosomes in macrophages from late Stage 11 embryos through colocalization with Golgin 84 and Hrs, using cells extracted from positions in the head adjacent to the germband (Figure 2I). We conclude that the T antigen enrichment on macrophages migrating towards and into the germband requires a previously uncharacterized atypical MFS with homology to sugar binding proteins that is localized predominantly to the Golgi and endosomes.

The MFS, Minerva, is required in macrophages for dissemination and germband invasion

We examined if CG8602 affects macrophage invasive migration. The CG8602EP3102 mutant displayed a 35% reduction in macrophages within the germband at early Stage 12 compared to the control (Figure 3A–B,D, Figure 3—figure supplement 1A). The same decrease is observed when the mutant is placed over the deficiency Df(3L)BSC117 that removes the gene entirely (Figure 3D), arguing that CG8602EP3102 is a genetic null for macrophage germband invasion. The P element transposon insertion itself causes the migration defect because its precise excision restored the number of macrophages in the germband to wild type levels (Figure 3D). Expression of the CG8602 gene in macrophages can rescue the CG8602EP3102 P element mutant (Figure 3C–D, Figure 3—figure supplement 1A), and RNAi knockdown of CG8602 in macrophages can recapitulate the mutant phenotype (Figure 3E, Figure 3—figure supplement 1B). Our data thus argue that CG8602 is required in macrophages themselves for germband invasion.

Figure 3 with 4 supplements see all
Download asset Open asset
CG8602, which we name Minerva, is required in macrophages for their efficient invasion of the germband.

(A–C) Representative confocal images of early Stage 12 embryos from (A) control, (B) P{EP}CG8602EP3102 = minerva (mrva)3102 mutant, and (C) mrva3102 mutants with macrophage expression of the gene rescued by srpHemo(macro)-mrva. Macrophages express srpHemo-3XmCherry (red) and the embryo autofluoresces (green). In the mutant, macrophages remain in the head and fail to enter the germband, hence we name the gene minerva. (D) Dashed ellipse in schematic at left represents the germband region in which macrophages (red) were counted throughout the study. Comparison of the control (n= 38), mrva3102 mutants (n = 37) and mrva3102 mutant/Df(3L)BSC117 that removes the gene (n = 23) shows that the mutant significantly decreases migration into the extended germband (p<0.0001 for control vs mutant, p=-0002 for control vs Df cross). This defect can be partially rescued by expression in macrophages of srpHemo >mrva::FLAG::HA (n = 18, p=0.222 for control vs rescue, p=0.036 for mutant vs rescue) and completely rescued by precise excision (mrvaΔ32) of the P element (n = 16, p=0.826). srpHemo >mCherry nls labeled the macrophages. (E–G) Macrophage quantification in early Stage 12 embryos. (E) Fewer germband macrophages upon expression of mrva RNAi v101575 only in macrophages under the control of srpHemo (n = 28–35 embryos, p<0.0001). (F) Fewer macrophages found on the yolk neighboring the germband (oval in schematic) in the mrva3102 mutant compared to control embryos (n = 14–16 embryos, p=0.0003). (G) Increased germband macrophage numbers in shgP34; mrva3102 compared to the mrva3102 mutant indicates a partial rescue from reducing DE-Cadherin which is expressed in the germband ectoderm (n = 19–29, p<0.0001, p=0.005). (H) No significant difference in number of macrophages labeled with srpHemo-3xmCherry in vnc segments (area in blue oval in schematic) between control and mrva3102 mutant embryos in fixed mid Stage 12 embryos (n = 23–25, p=0.55). Images from two-photon movies of (I) Stage 10 and (L) late Stage 11-early Stage 12 embryos in which macrophage nuclei (red) are labeled with srpHemo-H2A::3xmCherry. (I) Stills at 0 and 60 min and (J) quantification of macrophage speed reveal 33% slower macrophage migration in the head towards the yolk neighboring the germband in the mrva3102 mutant compared to the control, n = 3 movies for each, #tracks: control = 329, mutant = 340, p=0.002. Blue box in magnification in schematic indicates region analysed in J. (K) The first macrophage in mrva3102 mutants is much slower to enter the germband after macrophages reach the germband edge (control = 22.00 ± 1.53 min, n = 3, mrva3102 mutant = 102.0 ± 20.35 min, n = 4. p-value=0.021). (L) The time when macrophages reached the germband in each genotype was defined as 0’. Stills at 60 and 90 min and (M) quantification of macrophage speed reveal 43% slower macrophage migration in the germband in the mrva3102 mutant compared to the control. Blue arrow in schematic indicates route analyzed. n = 3 movies for each, #tracks: control = 21, mutant = 14, p=0.022. Significance was assessed by Kruskal-Wallis test with Conover post test comparison in D, G, Student’s t-test in E, F, H, J-K, M. ns = p > 0.05, *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001. Scale bars are 50 μm in A-C, 40 μm in I, 30 μm in L. See also Figure 3—figure supplement 1 and Figure 3—video 1–3.

https://doi.org/10.7554/eLife.41801.009
Figure 3—source data 1

Source data on the quantification of macrophages in the germband shown in Figure 3D–E,G and Figure 3—figure supplement 1A, on the yolk (Figure 3F) on the vnc (Figure 3H, Figure 3—figure supplement 1C) and in the whole embryo (Figure 3—figure supplement 1D–E).

Source data on the xyz position of macrophages from the tracks that form the basis of the analysis shown in Figure 3J–K,M and Figure 3—figure supplement 1F,G. Source data on the mismigration of germ cells, the levels of mrva expression in the ovary, and the migration of border cells (Figure 3—figure supplement 1I,J and L, respectively). Source data on the xyz position of macrophages in the movies of the mrva3102 mutant and the control underlying the analysis shown in Figure 3J-K,M and Figure 3—figure supplement 1F-G.

https://doi.org/10.7554/eLife.41801.011

Decreased numbers of macrophages in the extended germband could be caused by specific problems entering this region, or by general migratory defects or a decreased total number of macrophages. To examine the migratory step that precedes germband entry, we counted the number of macrophages sitting on the yolk next to the germband in fixed embryos in the CG8602EP3102 mutant. We observed a 30% decrease compared to the control (Figure 3F), suggesting a defect in early dissemination. Entry into the germband by macrophages occurs between the closely apposed DE-Cadherin expressing ectoderm and the mesoderm and is accompanied by deformation of the ectodermal cells (Ratheesh et al., 2018). We tested if reductions in DE-Cadherin could ameliorate the germband phenotype. Indeed, combining the CG8602EP3102 mutation with shgP34 which reduces DE-Cadherin expression (Pacquelet and Rørth, 2005; Tepass et al., 1996) produced a partial rescue (Figure 3G), consistent with CG8602 playing a role in germband entry as well as in an earlier migratory step. There was no significant difference in the number of macrophages migrating along the vnc in late Stage 12 compared to the control in fixed embryos (Figure 3H) from the CG8602EP3102 mutant or from a knockdown in macrophages of CG8602 by RNAi (Figure 3—figure supplement 1C), arguing against a general migratory defect. There was also no significant difference in the total number of macrophages in either case (Figure 3—figure supplement 1D–E). From analyzing the CG8602 mutant phenotype in fixed embryos we conclude that CG8602 does not affect later vnc migration but is important for the early steps of dissemination and germband invasion.

To examine the effect of CG8602 on macrophage speed and dynamics, we performed live imaging of macrophages labeled with the nuclear marker srpHemo-H2A::3xmCherry in control and CG8602EP3102 mutant embryos (Figure 3—video 1 and 2). We first imaged macrophages migrating from their initial position in the delaminated mesoderm up to the germband and detected a 33% decrease in speed (2.46 ± 0.07 μm/min in the control, 1.66 ± 0.08 μm/min in the CG8602EP3102 mutant, p=0.002) (Figure 3I,J) and no significant decrease in persistence (0.43 ± 0.02 in the control, 0.40 ± 0.01 in the mutant, p=0.22) (Figure 3—figure supplement 1F). We then examined the initial migration of macrophages into the germband at late Stage 11. We observed a range of phenotypes in the six movies we made of the mutant, with macrophages pausing at the germband edge from twice to six times as long as in the control before invading into the tissue (Figure 3K shows average time for entry, control = 22.00 ± 1.53 min, CG8602EP3102 mutant = 102.0 ± 20.35 min). As we observed no change in the timing of the initiation of germband retraction (269.6 ± 9 min in control and 267.1 ± 3 min in mutant, p=0.75) but did observe a decreased speed of its completion in the mutant (107 ± 12 min from start to end of retraction in control and 133 ± 6 min for mutant p=0.05), we only analyzed macrophages within the germband before its retraction begins. We observed a 43% reduction in macrophage speed within the germband (2.72 ± 0.32 μm/min in the control and 1.55 ± 0.04 μm/min in the mutant, p=0.02) (Figure 3L,M). To assess this phenotype’s specificity for invasion, we used live imaging of macrophage migration along the inner vnc that occurs during the same time period as germband entry; we observed no significant change in speed (2.41 ± 0.06 μm/min in the control and 2.23 ± 0.01 μm/min in the mutant, p=0.11) or directionality (0.43 ± 0.03 in the control and 0.43 ± 0.02 in the mutant, p=0.9742) (Figure 3—figure supplement 1G, Figure 3—video 3). We conclude from the sum of our experiments in fixed and live embryos that CG8602 is important for the initial disseminatory migration out of the head and for invasive migration into and within the germband, but does not alter general migration. We name the gene minerva (mrva), for the Roman goddess who was initially trapped in the head of her father, Jupiter, after he swallowed her pregnant mother who had turned herself into a fly.

Minerva is not required for border cell invasion or germ cell migration

To assess if Minerva only affects macrophage invasion or also other types of tissue penetration in Drosophila, we examined the migration of germ cells and border cells. Germ cells move in an Integrin-independent fashion through gaps in the midgut created by ingressing formerly epithelial cells (Devenport and Brown, 2004; Seifert and Lehmann, 2012). We found no defect in germ cell migration when examining control and mrva3102 mutant embryos stained with the Vasa Ab (Figure 3—figure supplement 1H–I). Border cells are born in the epithelia surrounding the ovary and then delaminate to move invasively between the nurse cells towards the oocyte (Montell, 2003), guided by the same receptor that macrophages use during their embryonic dispersal, PVR (Duchek et al., 2001). They migrate as a tumbling collective, using invadopodia and Cadherin-based adhesion to progress (Cai et al., 2014; Niewiadomska et al., 1999). mrva is expressed in dissected control ovaries and the mrva3102 mutant reduces the levels of mrva RNA in the ovary by 70%, similar to the reduction observed in macrophages (Figure 3—figure supplement 1J). We identified border cells by staining with DAPI to detect their clustered nuclei. We observed no significant change in border cell migration towards the oocyte in the mrva3102 mutant compared to the control (Figure 3—figure supplement 1K–L). These results support the conclusion that Mrva is not generally required for all migratory cells that move confined through tissues during development, but specifically for the invasion of macrophages, which is an Integrin-dependent process (Siekhaus et al., 2010).

Minerva affects a small fraction of the Drosophila embryonic O-glycoproteome

We set out to determine if Minerva induces T glycoforms on particular proteins. We first conducted a Western Blot with a mAb to T antigen on whole embryo extracts. We used the whole embryo because we were unable to obtain enough protein from FACS sorted macrophages or to isolate CRISPR-induced full knockouts of minerva in the S2R+ macrophage like cell line. We observed that several bands detected with the anti-T mAb were absent or reduced in the minerva mutant (Figure 4A), indicating an effect on the T antigen modification of a subset of proteins.

Figure 4 with 1 supplement see all
Download asset Open asset
Glycoproteomic analysis reveals Minerva is required for higher levels of T-antigen on a subset of proteins.

(A) Representative Western blot of protein extracts from Stage 11/12 control and mrva3102 mutant embryos probed with T antigen antibody. Arrows indicate decreased/missing bands in the mutant compared to the control. Profilin serves as a loading control (n = 10 biological replicates). (B) Summary of glycomics results on wild type embryos. (C) Venn diagram indicating number of glycosites or proteins found with T, Tn or T and Tn antigen modifications in the wild type. (D) Plot showing the number of T and Tn antigen glycosites per protein in the total glycoproteome and on proteins that show three (blue) and ten-fold (red) altered glycopeptides in the mrva3102 mutant. Proteins strongly affected by Minerva have a higher number of glycosites (p=0.005). (E) Summary of glycomics on mrva3102 embryos showing the numbers of proteins and glycosites exhibiting three (blue) or ten (red) fold changes in T and Tn antigen levels. (F) T antigen (in green) and Tn antigen (orange) occupied glycosites plotted against the ratio of the levels of glycopeptides found for each glycosite in the mrva3102 mutant/control. Higher positions on the plot indicate a lower level of glycosylation in the mutant. Blue dashed line represents the cut off for 3x changes in glycosylation, and the red dotted line the 10x one. (G) Venn diagram of the number of proteins with at least three fold change in the T antigen (T, green) or Tn antigen (Tn, orange) glycosylation in the mrva3102 mutant. Up arrows denote increase, down arrows indicate decrease in levels. (H) Proteins with at least a three fold decrease in T antigen levels in the mrva3102 mutant. Glycan modified amino acids are highlighted in bold green font. Unchanged/Higher GS column indicates if any other glycosite on the protein is unchanged or increased. Table does not show the two chitin and chorion related genes unlikely to function in macrophages. G: Golgi, ES: Extracellular space, Endo: Endosomes, ER: Endoplasmic reticulum, ECM: Extracellular Matrix, PM: Plasma Membrane, GS: Glycosite. Cancer links as follows. 1) QSOX1: Promotes cancer invasion in vitro, overexpression worse patient outcomes (Katchman et al., 2013; Katchman et al., 2011). 2) HYOU1: Overexpression associated with vascular invasion, worse patient outcomes (Stojadinovic et al., 2007) (Zhou et al., 2016). 3) TMEM87B: translocation breakpoint in cancer, (Hu et al., 2018). 4) ACVR2B: over expressed in renal cancer (Senanayake et al., 2012). 5) GANAB: inhibits cancer invasion in vitro (Chiu et al., 2011). 6) LRIG1: inhibits cancer invasion in vitro, and in mice (Sheu et al., 2014), (Mao et al., 2018). (I) Annotated ETD MS2 spectra of the VHQPSATPASK glycopeptide from Qsox1 with T antigen glycosylation at position T7. See schematic in which the yellow square represents GalNAc and the yellow circle Gal. Assigned fragment ions in MS2 spectra are highlighted by red for ‘c’ type fragments (those retaining the original N terminus) and blue for ‘z’ type fragments (those retaining the original C terminus). The graph at the left shows the relative quantification of the glycopeptide precursor ion’s peak area in the control and mrva3102 mutant plotted on a logarithmic scale. See also Figure 4—figure supplement 1, Figure 4-Dataset 1, Supplementary file 1–3.

https://doi.org/10.7554/eLife.41801.016

We wished to obtain a more comprehensive view of the proteins affected by Minerva. Since there is little information about Drosophila O-glycoproteins and O-glycosites (Schwientek et al., 2007; Aoki and Tiemeyer, 2010), we used lectin-enriched O-glycoproteomics to identify proteins displaying T and Tn glycoforms in Stage 11/12 embryos from wild type and mrva3102 mutants (Figure 4—figure supplement 1A). We labeled tryptic digests of embryonic protein extracts from control or mutant embryos with stable dimethyl groups carrying medium (C2H2D4) or light (C2H6) isotopes respectively to allow each genotype to be identified in mixed samples (Boersema et al., 2009; Schjoldager et al., 2012; Schjoldager et al., 2015). The pooled extracts were passed over a Jacalin column to enrich for T and Tn O-glycopeptides; the eluate was analyzed by mass spectrometry to identify and quantify T and Tn modified glycopeptides in the wild type and the mutant sample through a comparison of the ratio of the light and medium isotope labeling channels for each glycopeptide (see Figure 4—figure supplement 1B–C for example spectra).

In the wild type we identified T and Tn glycopeptides at 936 glycosites derived from 270 proteins (Supplementary file 1 and Figure 4B). 62% of the identified O-glycoproteins and 77% of identified glycosites contained only Tn O-glycans. 33% of the identified O-glycoproteins and 23% of glycosites displayed a mixture of T or Tn O-glycans, and 5% of identified O-glycoproteins and 4% of glycosites had solely T O-glycans (Figure 4C). In agreement with previous studies (Steentoft et al., 2013), only one glycosite was found in most of the identified O-glycoproteins (44%) (Figure 4D). In 20% we found two sites, and some glycoproteins had up to 27 glycosites. The identified O-glycosites were mainly on threonine residues, (78.5%) with some on serines (21.2%) and very few on tyrosines (0.3%) (Figure 4—figure supplement 1D). Metabolism, cuticle development, and receptors were the most common functional assignments for the glycoproteins (Figure 4—figure supplement 1E).

We sought to assess the changes in glycosylation in the mrva mutant. A majority of the quantifiable Tn and T O-glycoproteome was unaltered between the wild type and the mrva3102 mutant, with only 63 proteins (23%) showing more than a three-fold change and 18 (6%) a ten-fold shift (Figure 4F). We observed both increases and decreases in the levels of T and Tn modification on proteins in the mutant (Figure 4F–G, Supplementary file 1 and 2), but a greater number of proteins showed decreased rather than increased T antigen levels. 67% of the vertebrate orthologs of Drosophila proteins displaying shifts in this O-glycosylation have previously been linked to cancer (Figure 4H, Supplementary file 2). These proteins were affected at specific sites, with 40% of glycosites on these proteins changed more than three fold and only 14% more than ten fold. The glycosite shifts in T antigen occurred either without significant alterations in Tn (33% of glycosites had only decreased T antigen, 17% of glycosites had only increased T antigen) or with changes in T antigen occurring in the same direction as the changes in Tn (22% of glycosites both Tn and T antigen increased, 22% of glycosites both Tn and T decreased) (Supplementary file 2). Only 1% of glycosites displayed decreased T antigen with a significant increase in Tn. Interestingly, a higher proportion of the glycoproteins with altered O-glycosylation in the mrva3102 mutant had multiple glycosites than the general glycoproteome (Figure 4D) (p value=0.005 for ten-fold changes). We conclude that Minerva affects O-glycosylation occupancy on a small subset of O-glycoproteins, many of whose vertebrate orthologs have been linked to cancer, with both T and Tn O-glycopeptides being affected.

Minerva raises T antigen levels on proteins required for invasion

Given that blocking Tn to T conversion through the knockdown of the C1GalTA enzyme resulted in a germband invasion defect, we examined the known functions of the 18 proteins with lower T antigen in the absence of Minerva to distinguish which processes Minerva could influence to facilitate invasion (Figure 4H). We excluded two proteins involved in eggshell and cuticle production. To spot proteins whose reduced T antigen-containing glycopeptides are caused directly by alterations in glycosylation rather than indirectly by decreased protein expression in the mrva mutant, we checked if glycosylation at other identified glycosites was unchanged or increased. We identified ten such proteins, several of which were in pathways that had been previously linked to invasion in vertebrates. Qsox1, a predicted sulfhydryl oxidase required for the secretion and thus potential folding of EGF repeats (Tien et al., 2008) showed the strongest alterations of any protein, with a 50-fold decrease in T antigen levels in the mrva mutant (Figure 4I). The mammalian ortholog QSOX1 has been shown to affect disulfide bond formation, is overexpressed in some cancers, promotes Matrigel invasion, and can serve as a negative prognostic indicator in human cancer patients (Chakravarthi et al., 2007; Katchman et al., 2011; Lake and Faigel, 2014). Dtg, with a 13-fold reduction in T antigen (Hodar et al., 2014), and Put with a five-fold reduction (Letsou et al., 1995) respond to signaling by the BMP-like ligand, Dpp. Dpp signaling directs histoblast invasion in the fly (Ninov et al., 2010). Gp150 shows a four fold decrease in T antigen and modulates Notch signaling (Fetchko et al., 2002; Li et al., 2003). Notch and BMP promote invasion and metastasis in mice (Bach et al., 2018; Garcia and Kandel, 2012; Owens et al., 2015; Pickup et al., 2015; Sahlgren et al., 2008; Sonoshita et al., 2011). We conclude that Mrva is required to increase T O-glycans on a subset of the glycosites of selected glycoproteins involved in protein folding, glycosylation and signaling in pathways frequently linked to promoting cancer metastasis. Its strongest effect is on a predicted sulfhydryl oxidase, the Drosophila ortholog of the mammalian cancer protein, QSOX1.

We wished to determine how Qsox1 might affect Drosophila macrophage germband invasion. Embryos from the KG04615 P element insertion in the 5’UTR of the qsox1 gene displayed 42% fewer macrophages in the germband compared to the control (Figure 5A,B) with an increase in macrophages remaining on the yolk (Figure 5—figure supplement 1A). We observed a small decrease in migration along the vnc (Figure 5—figure supplement 1B) and no change in total macrophage numbers in these embryos (Figure 5—figure supplement 1C). These migration phenotypes were also observed in embryos in which RNAi line v108288 knocked down qsox1 only in macrophages (Figure 5C, Figure 5—figure supplement 1D–E). We then conducted live imaging (Figure 5D, Figure 5—video 1) (compare to control shown in Figure 3—video 1) to examine how the qsox1KG04615 mutant affected the dynamics of macrophage migration. During the movement of macrophages labeled with the nuclear marker srpHemo-H2A::3xmCherry from their initial position up to the germband we detected an 18% decrease in speed (Figure 5E) (2.46 ± 0.07 μm/min in the control, 2.02 ± 0.03 μm/min in the qsox1KG046152 mutant, p=0.006, n = 3) and no significant decrease in persistence (Figure 5—figure supplement 1F) (0.43 ± 0.02 in the control, 0.39 ± 0.01 in the mutant, p=0.13). Macrophages in the qsox1 mutant were delayed twice as long at the germband edge before entering (Figure 5F) (time to entry 22.00 ± 1.53 min in the control and 49.67 ± 9.33 min in the qsox1KG046152 mutant, n = 3). Once in, they moved within the germband with a 17% slower speed, a reduction that was not statistically significant (Figure 5G) (2.72 ± 0.32 μm/min in the control, 2.27 ± 0.20 μm/min in the qsox1KG046152 mutant, p=0.30, n = 3). We conclude that Qsox1 aids the disseminatory migration of macrophages but is most strongly required for their initial invasion into the germband tissues.

Figure 5 with 2 supplements see all
Download asset Open asset
Qsox1 is required for macrophage dissemination and entry into the germband tissue.

(A) Representative confocal images of early Stage 12 embryos from control and P{SUPor-P}Qsox1KG04615 = qsox1KG04615. (B–C) Quantification in early Stage 12 embryos showing a significant reduction in germband macrophages (B) in the P-element mutant qsox1KG04615 located in the Qsox1 5’UTR (n = 18, p=0.0012) and (C) upon the expression in macrophages under srpHemo-GAL4 control of an RNAi line (v108288) against Qsox1 (n = 24, 23 embryos, p=0.001). (D) Images from two-photon movies from control and qsox1KG04615. Macrophage nuclei (red) are labeled with srpHemo-H2A::3xmCherry. Stills at 0, 60, 90, 120, 150 and 180 min. (E) Quantification of macrophage speed reveals 18% slower macrophage migration in the head towards the yolk neighboring the germband in the qsox1KG04615 mutant compared to the control (n = 3 movies for each, #tracks: control = 329, mutant = 396, p=0.0056). (F) Quantification of the time required for macrophage entry into the germband in qsox1KG04615 compared to the control. n = 3 movies for each, p=0.043. (G) Quantification of macrophage speed in the germband in the qsox1KG04615 mutant compared to the control (n = 3 movies for each, #tracks: control = 21, mutant = 19, p=0.300). (H) Pearson’s Coefficient analysis indicating the level of colocalisation of a MT-Qsox1::FLAG::HA construct transfected into S2R+ cells visualized with an HA antibody and antibodies against markers for the ER (Cnx99a), the Golgi (Golgin 84, Golgin 245, and GMAP), the early endosome (Hrs), the late endosome (Rab7) and the nucleus (DAPI) (n = 11–15) as well as with a srpHemo-mrva::3xmCherry construct (n = 18). (I) Western blot of concentrated supernatant collected from S2R+ cells transfected with srpGal4 UAS-qsox1::FLAG::HA (first three lines) and S2R+ cells that are untransfected. (J) Quantification of intracellular LanA intensity along a 4 μm line in macrophages (as indicated in schematic) from the control (black), minerva3102 (blue) and the qsox1KG04615 mutants (orange) (n = 4–5 embryos, 80–100 cells, 240–300 lines). For the whole graph see Figure 5—figure supplement 1G–J. Scale bars 50 μm for A, 30 μm in D. B-C, E-G and J were analyzed with Student’s test. ns = p > 0.05, *p<0.05, **p<0.01, ***p<0.001. See also Figure 5—figure supplement 1.

https://doi.org/10.7554/eLife.41801.018
Figure 5—source data 1

Source data on the quantification of macrophages in the germband shown in Figure 5B-C, on the yolk shown in Figure 5—figure supplement 1A,1D, on the vnc shown in Figure 5—figure supplement 1B,1E, and in the whole embryo shown in Figure 5—figure supplement 1C.

Source data on the xyz position of macrophages from the tracks that form the basis of the analysis shown in Figure 5E-G. Source data on the quantification of the Pearson's coefficient for Qsox1 colocalization with different markers shown in Figure 5H and the quantification of LanA intensity shown in Figure 5J and Figure 5—figure supplement 1L-N. Source data on the xyz position of macrophages in the movies of the qsox1KG04615 mutant underlying the analysis shown in Figure 5E-G and Figure 5—figure supplement 1F.

https://doi.org/10.7554/eLife.41801.020

We wished to examine how Qsox1 could be exerting this effect on macrophage tissue entry. Vertebrate QSOX1 has been shown to localize to the Golgi and act as a sulfhydryl oxidase, catalyzing disulfide bond formation and protein folding (Alon et al., 2012; Chakravarthi et al., 2007; Heckler et al., 2008; Hoober et al., 1996). The Drosophila protein has been shown to be required for the secretion of multimerized EGF domains and was hypothesized to act redundantly with ER oxidoreductin-like-1 to form disulfide bonds (Tien et al., 2008). We found that an HA-tagged form of Qsox1 transfected into the Drosophila macrophage like cell line, S2R+, colocalizes little with markers for the ER, and considerably with those for Golgi and endosomes (Figure 5H, Figure 5—figure supplement 1G–I). We also observed significant colocalization with 3xmCherry-tagged Mrva (Figure 5H, Figure 5—figure supplement 1J). Vertebrate QSOX1 can be cleaved from its transmembrane domain to allow secretion (Rudolf et al., 2013), and has been shown in vitro to be required extracellularly for the incorporation of laminin produced by fibroblasts into the extracellular matrix (ECM), thereby supporting efficient cancer cell migration (Ilani et al., 2013). Drosophila Qsox1 also has a transmembrane domain, yet we detected an HA-tagged form in the media after transfection into S2R+ cells (Figure 5I), indicating that it can be secreted. To examine if Drosophila Qsox1 might also affect Laminin, we stained mrva3102 and qsox1KG046152 mutant embryos with an antibody against Laminin A (LanA) (Figure 5—figure supplement 1K). In both mutants we observed increased amounts of LanA inside and somewhat higher levels adjacent to the macrophages, but no significant alteration at the cell edges compared to the control (Figure 5J, Figure 5—figure supplement 1L–N). We conclude that Drosophila Qsox1 can be secreted but is also found in the Golgi and endosomes like Mrva, and that both proteins affect LanA, a component of the ECM.

Conservation of Minerva’s function in macrophage invasion and T antigen modification by its mammalian ortholog MFSD1

To determine if our studies could ultimately be relevant for mammalian biology and therefore also cancer research, we searched for a mammalian ortholog. MFSD1 from mus musculus shows strong sequence similarity with Mrva, with 50% of amino acids displaying identity and 68% conservation (Figure 6A, Figure 6—figure supplement 1A). A transfected C-terminally GFP-tagged form (Figure 6—figure supplement 1B) showed localization to the secretory pathway, colocalizing with the Golgi marker GRASP65 in murine MC-38 colon carcinoma, 4T1 breast cancer cells and LLC1.1 lung cancer (Figure 6B–C, Figure 6—figure supplement 1C–E) and with Golgi and endosomal markers in B16-BL6 melanoma cells (Figure 6C, Figure 6—figure supplement 1F). mmMFSD1 expression in macrophages in mrva3102 mutant embryos can completely rescue the germband invasion defect (Figure 6D–E). This macrophage-specific expression of MFSD1 also resulted in higher levels of T antigen on macrophages when compared to those in mrva3102 mutants (Figure 6F–G). Thus MFSD1 not only displays localization in the Golgi apparatus in multiple types of mammalian cancer but can also rescue O-glycosylation and migration defects when expressed in Drosophila, arguing that the functions Mrva carries out to promote invasion into the germband are conserved up to mammals.

Figure 6 with 1 supplement see all
Download asset Open asset
Minerva’s murine ortholog, MFSD1, can substitute for Minerva’s functions in migration and T-antigen glycosylation.

(A) Topology prediction of mouse MFSD1 (NP_080089.1) using the online tools TMPred (Hofman and Stoffel, 1993) and Protter (Omasits et al., 2014). 50% of amino acids are identical between the M. musculus MFSD1 and D. melanogaster sequence of mrva (CG8602) (NP_648103.1) and are highlighted in dark blue, similar amino acids are in light blue. (B) Confocal images of MC-38 colon carcinoma cells showing colocalization of MFSD1-eGFP (green) with the Golgi marker GRASP65 (red). DAPI labels the nucleus (blue). (C) Quantitation using Fiji of the colocalization of MFSD1-eGFP with the Golgi marker (GRASP65), early endosome marker (Rab5), late endosome marker (Rab7), and lysosome marker (LAMP1) in MC-38 colon carcinoma, B16-BL6 melanoma, LLC1 Lewis lung carcinoma, and 4T1 breast carcinoma cells. Representative images are shown in Figure 6—figure supplement 1C–F (n = 8–15, 5–9, 4–9, 5–10 cells per condition within the respective cancer types). (D) Confocal image of a Stage 12 fixed embryo showing that expression of mmMFSD1 in macrophages under the direct control of the srpHemo(macro) promoter in the mrva3102 mutant can rescue the defect in macrophage migration into the germband. Compare to Figure 3A,B. Macrophages visualized with srpHemo-H2A::3xmCherry for D-E. (E) Quantitation of the number of macrophages in the germband of early Stage 12 embryos from the control (n = 25), mrva3102 mutants (n = 29), and mrva3102 srpHemo(macro)-mmMFSD1 (n = 13, p=0.0005 for mutant vs control, p<0.0001 for mutant vs rescue). (F) Quantification of T antigen levels on macrophages in late Stage 11 embryos from control, mrva3102mutant and mrva3102 srpHemo(macro)-mmMFSD1 embryos. T antigen levels normalized to those observed in the control (n = 8–9 embryos, 280, 333, and 289 cells quantified respectively, p<0.0001 for both). (G) Confocal images of macrophages (red) on the germband border stained with T antigen antibody (green) in the control, the mrva3102 mutant, and mrva3102 srpHemo(macro)-mmMFSD1 shows that mmMFSD1 expression in macrophages can rescue the decrease of macrophage T antigen observed in the mrva3102 mutant. Macrophages visualized with srpHemo-3xmCherry for F-G. (H) Model for Minerva’s function during macrophage invasion based on our findings and the literature: Minerva in the Golgi (grey) leads to increases in T antigen levels on a subset of proteins that aid invasion, including Qsox1 which regulates protein folding through disulfide bond formation and isomerization. We propose that increased T antigen on Qsox1 facilitates its sulfhydryl oxidase activity that aids the formation of a robust crosslinked ECM which macrophages utilize during tissue entry. Significance was assessed by Kruskal-Wallis test with Conover post test analysis in E,F). ***p<0.001, ****p<0.0001. Scale bars are 10 μm in B, 50 μm in D, and 3 μm in G. See also Figure 6—figure supplement 1.

https://doi.org/10.7554/eLife.41801.022
Figure 6—source data 1

Source data on the quantification of Pearson’s coefficient for MFSD1 colocalization with different markers (Figure 6C), the number of macrophages in the germband (Figure 6E) and the level of T antigen in macrophages (Figure 6F).

https://doi.org/10.7554/eLife.41801.024

Discussion

O-glycosylation is one of the most common posttranslational modifications, yet the intrinsic technical challenges involved in identifying O-glycosites and altered O-glycosylation on a proteome-wide level has hampered the discovery of biological functions (Levery et al., 2015). Here we provide two important new advances for the field. First, we identify a key regulator of this O-glycosylation, Minerva, with an unexpected role for a member of the major facilitator superfamily. Our demonstration that this conserved protein affects invasion and the appearance of the cancer-associated core1 T glycoform on a set of proteins connected to invasion provides a new perspective on T glycoform regulation and may have implications for cancer. Second, we define the GalNAc-type O-glycoproteome of Drosophila embryos. As O-glycosites cannot as yet be reliably predicted, our proteomic characterization in a highly genetically accessible organism will permit future studies on how glycosylation affects cell behavior; we highlight T and Tn O-glycosylated receptors in Supplementary file 3 to further this goal.

Modifications of the O-glycoproteome by an MFS family member

Our identification of a MFS family member as a regulator of O-glycosylation is surprising. MFS family members can serve as transporters and shuttle a wide variety of substrates (Quistgaard et al., 2016; Reddy et al., 2012). Minerva displays homology to sugar transporters and is localized to the Golgi and endosomes. Minerva could thus affect O-glycosylation in the Golgi through substrate availability. However, the lower and higher levels of glycosylation in the mrva3102 mutant we observe are hard to reconcile with this hypothesis. Given that the changes in T antigen on individual glycosites in the mrva mutant are found either with no significant change in Tn or with a change in the same direction (Supplementary file 1 and 2), regulation appears to occur at the initial GalNAc addition on the protein subset as well as on further T antigen elaboration. 95% of the proteins with 10-fold altered glycosylation in the mrva mutant had multiple O-glycosylation sugar modifications compared to 56% of the general O-glycoproteome. Greatly enhanced glycosylation of protein sequences containing an existing glycan modification is observed for some GalNAc-Ts due to a lectin domain (Hassan et al., 2000; Kubota et al., 2006; Revoredo et al., 2016) and Minerva could theoretically affect such a GalNAc-T in Drosophila. Alternatively, Minerva, while in the ‘outward open’ conformation identified for MFS structures (Quistgaard et al., 2016), may itself have a lectin-like interaction with Tn and T glycoforms that have already been added on a loop of particular proteins. Minerva’s binding could open up the target protein’s conformation to increase or block access to other potential glycosites and thus affect the final glycosylation state on select glycoproteins.

The changes we see in O-glycosylation are also likely due to a combination of Minerva’s direct and indirect effects. O-GalNAc modification of vertebrate Notch can affect Notch signaling during development (Boskovski et al., 2013); the Drosophila ortholog of the responsible GalNAc transferase is also essential for embryogenesis (Bennett et al., 2010; Schwientek et al., 2002). A GalNAcT in Xenopus can glycosylate a peptide corresponding to the ActR IIB receptor and inhibit Activin and BMP type signaling (Herr et al., 2008; Voglmeir et al., 2015). Thus the changed glycosylation we observe on components of the Notch and Dpp pathways could alter transcription (Hamaratoglu et al., 2014; Ntziachristos et al., 2014), shifting protein levels and thereby changing the ratio of some glycopeptides in the mrva mutant relative to the wild type. Proteins in which glycosylation at other sites is unchanged or changed in the opposite direction are those most likely to be directly affected by Minerva. Such proteins include ones involved in protein folding and O-glycan addition and removal (Figure 4H) (Tien et al., 2008). If changes in the glycosylation of these proteins alters their specificity or activity, some of the shifts we observe in our glycoproteomic analysis could be indirect in a different way; an initial effect of Minerva on the glycosylation of regulators of protein folding and glycosylation could change how these primary Minerva targets affect the glycosylation of a second wave of proteins.

An invasion program regulated by Minerva

The truncated immature core1 T and Tn O-glycans are not usually present in normal human tissues but exposure of these uncapped glycans has been found on the majority of cancers and serves as a negative indicator of patient outcome (Fu et al., 2016; Springer, 1984). Increases in Tn antigen due to a shift in GalNAcT localization to the ER promote invasion and metastasis (Gill et al., 2013). An antibody against T antigen has decreased the metastatic spread of cancer cells in mice (Heimburg et al., 2006). Here we further strengthen the case for a causative relationship between T antigen modification and the invasive migration that underlies metastasis. The transient appearance of T antigen in human fetuses (Barr et al., 1989) and the conserved function of Minerva lead us to propose that the change in O-glycosylation in cancer represents the reactivation of an ancient developmental program for invasion. Our embryonic glycoproteome analysis identifies 106 T antigen modified proteins, a very large set to investigate. However, the absence of Mrva causes invasion defects and deficits in T antigen modification on only 10–20 proteins; these include components involved in protein folding, glycosylation modification, and the signaling pathways triggered by Notch and the BMP family member, Dpp.

Our working model is that the defect in germband tissue invasion seen in the mrva mutant is caused by the absence of T antigen on this group of proteins that act coordinately (Figure 6H). 56% of these have vertebrate orthologs, and 55% of those have already been linked to cancer and metastasis. The vertebrate ortholog of Qsox1, the protein with the largest changes in T antigen in the mrva mutant, can enhance cancer cell invasion in in vitro assays and higher levels of the protein have been associated with poor patient outcomes (Katchman et al., 2013; Katchman et al., 2011). We find that the strongest effect of Drosophila Qsox1 on macrophage migration is to reduce the time by two fold that macrophages take sitting at the germband edge before they successfully begin to invade into the germband tissues. We also observe in qsox1 and mrva mutants that LanA levels are higher within the macrophages and somewhat elevated near but not at the macrophage cell edges. This could be due to some combination of the following shifts in cellular processes: an increase in LanA production, a decrease in its degradation, a slowing of its secretion or a speeding of its diffusion. We base our model on the functions that have been previously defined for the Qsox1 sulfhydryl oxidase family, in integrating laminin into the ECM (Ilani et al., 2013) and aiding secretion of EGF domains (Tien et al., 2008) which are found in Drosophila Laminins. If Qsox1 is needed for the efficient secretion and integration of LanA into the ECM, its absence could result in a less robustly cross-linked matrix. ECM crosslinking has been shown to enhance Integrin signaling, focal adhesion formation, and invasion of mammalian tumor cells (Levental et al., 2009). In its absence Drosophila macrophages which utilize Integrin during invasion (Siekhaus et al., 2010) and whose invasive migration is accompanied by deformation of the flanking tissue (Ratheesh et al., 2018), could be unable to generate sufficient traction forces to enter. Indeed, mutating another subunit of the Drosophila Laminin trimer, LanB1, reduces both normal LanA deposition and germband invasion by macrophages (Matsubayashi et al., 2017; Sánchez-Sánchez et al., 2017). A determination of the effect of Minerva’s regulation awaits a characterization of Qsox1 mutated such that it is incapable of being modified by T antigen on the Mrva-dependent sites. Nonetheless, the similarity of the changes in LanA we observe in the mrva3102 and qsox1KG046152 mutant supports the conclusion that Mrva dependent T-antigen modification of Qsox1 is necessary for its activity on some substrates. Given that mrva3102 mutants take even longer than qsox1KG04615 to enter germband tissue and display much stronger defects thereafter, we propose that T antigen modifications on other proteins are also crucial for tissue entry, and underlie the defect in invasive migration within the germband.

Minerva’s vertebrate ortholog, MFSD1, can rescue macrophage migration defects and restores higher T antigen levels. Tagged versions of Minerva’s vertebrate ortholog, MFSD1, detected the protein in lysosomes in HeLa and rat liver cells (Chapel et al., 2013; Palmieri et al., 2011). In four metastasizing mouse tumor cell lines we find MFSD1 mainly in the Golgi, where O-glycosylation is known to occur (Bennett et al., 2012). We do not yet know if invasion and metastasis is altered by the absence of MFSD1 but will be testing this in future work. Akin to how kinases add phospho-groups to affect a set of proteins and orchestrate a particular cellular response, we propose that Minerva in Drosophila macrophages and its vertebrate ortholog MFSD1 in cancer trigger changes in O-glycosylation that coordinately modulate, activate and inhibit a protein group to affect cellular dissemination and tissue invasion.

Materials and methods

Key resources table
DesignationSource or referenceIdentifiersAdditional
information
mrvaNAFlyBase:FBgn0035763
qsox1NAFlyBase: FBgn0033814
C1GalTANAFlyBase: FBgn0032078
srp-Gal4PMID: 15239955
srp-3xmCherryPMID: 29321168RRID:BDSC_78358 and 78359
srp-H2A::3xmCherryPMID: 29321168RRID:BDSC_78360 and 78361
UAS-CG8602::FLAG::HAPMID: 22036573
mrva3102Bloomington Drosophila Stock Center (BDSC), RRID:SCR_006457RRID:BDSC_17262
Df(3L)BSC117BDSC, RRID:SCR_006457RRID:BDSC_8976
UAS-mCherry.NLSBDSC, RRID:SCR_006457RRID:BDSC_38425
C1GalTA2.1BDSC, RRID:SCR_006457RRID:BDSC_28834
C1GalTA RNAi 1Vienna Drosophila Resource Centre (VDRC), RRID:SCR_013805VDRC: 2826
C1GalTA RNAi 2VDRC, RRID:SCR_013805VDRC: 110406
CG8602 RNAiVDRC, RRID:SCR_013805VDRC: 101575
qsox1RNAiVDRC, RRID:SCR_013805VDRC: 108288
qsox1 KG04615BDSC, RRID:SCR_006457RRID:BDSC_13824
MC-38OtherGift from Borsig lab, Univ of Zurich (UZH)
4T1OtherATCC Cat# CRL-2539, RRID:CVCL_0125Gift from Borsig lab, UZH
LLC1OtherATCC Cat# CRL-1642, RRID:CVCL_4358Gift from Borsig lab, UZH
B16-BL6OtherNCI-DTP Cat# B16BL-6, RRID:CVCL_0157Gift from Borsig lab, UZH
S2R+OtherGift from Frederico Mauri of the Knoblich lab at IMBA, Vienna
srpHemo-CG8602::3xmCherrythis paperCG8602 amplified from genome cloned into DSPL172 (PMID: 29321168)
MT-CG8602::FLAG::HADrosophila Genomic Resource Center (DGRC), RRID:SCR_002845DGRC: FMO06045
MT-Qsox1::FLAG::HADGRC, RRID:SCR_002845DGRC: FMO06379
PTS1-GFPOtherGift from Dr. McNew
MFSD1-eGFPthis paperMFSD1 amplified from dendritic cell cDNA library, inserted into Doxycycline inducible
expression vector pInducer20
Anti-GFP clone 2B6OtherGift from Ogris lab, MFPL Vienna; (1:100) for WB
Anti-GFP clone 5G4OtherGift from Ogris lab, MFPL Vienna; (1:50) for immunochemistry
Anti-T-antigen (mouse monoclonal)PMID: 23584533(1:5 for
immunochemistry; 1:10 for WB)
Anti-profilin (mouse monoclonal)Developmental Studies
Hybridoma Bank (DSHB), RRID:SCR_013527		DSHB Cat# chi 1J, RRID:AB_528439(1:50)
Anti-GAPDH (rabbit monoclonal)Abcam, RRID:SCR_012931Abcam Cat# ab181603, RRID:AB_2687666(1:10000) for WB
Anti-GRASP65 (rabbit polyclonal)Thermo Fisher Scientific, RRID:SCR_008452ThermoFischer Cat# PA3-910, RRID:AB_2113207(1:200) for immunochemistry
Anti-Rab5 (rabbit monoclonal)Cell Signaling Technology (CST), RRID:SCR_004431, Clone C8B1CST Cat# 3547, RRID:AB_2300649(1:200) for immunochemistry
Anti-Rab7 (rabbit monoclonal)CST, RRID:SCR_004431, Clone D95F2CST Cat# 9367, RRID:AB_1904103(1:200) for immunochemistry
Anti-LAMP1 (rabbit polyclonal)Abcam, RRID:SCR_012931Abcam Cat# ab24170, RRID:AB_775978(1:200) for immunochemistry
Anti- Cnx99a (mouse monoclonal)DSHB, RRID:SCR_013527DSHB Cat# Cnx99A 6-2-1, RRID:AB_2722011(1:5)
Anti- Hrs 27.4 (mouse monoclonal)DSHB, RRID:SCR_013527DSHB Cat# Hrs 27–4, RRID:AB_2618261(1:5)
Anti- Golgin 84
(mouse monoclonal)		DSHB, RRID:SCR_013527DSHB Cat# Golgin8412–1, RRID:AB_2722113(1:5)
Anti Rab7 (mouse monoclonal)DSHB, RRID:SCR_013527DSHB Cat# Rab7, RRID:AB_2722471(1:5)
Anti-GMAP (goat polyclonal)DSHB, RRID:SCR_013527DSHB Cat# GMAP, RRID:AB_2618259(1:50)
Anti- Golgin 245 (goat polyclonal)DSHB, RRID:SCR_013527DSHB Cat# Golgin245, RRID:AB_2618260(1:50)
Anti- HA (rat monoclonal)Roche, RRID:SCR_001326Roche Cat# 3F10, RRID:AB_2314622(1:50)
Anti-LanA (rabbit polyclonal)PMID:9257722gift from Stefan Baumgartner
(1:500)
Anti-Vasa (rat monoclonal)DSHB, RRID:SCR_013527DSHB Cat# anti-vasa, RRID:AB_760351(1:25)
Alexa 488- or 557- or 633- secondariesThermo Fisher Scientific, RRID:SCR_008452(1:500 for 488 and 557; 1:100 for 633)
Goat-anti-rabbit IgG (H + L)-HRPBioRadBio-Rad Cat# 170–6515, RRID:AB_2617112(1:10000)
Goat-anti-mouse IgG (H/L):HRPBioRadBio-Rad Cat# 170–6516, RRID:AB_11125547(1:10000)
LysoTracker Green DND-26Invitrogen, RRID:SCR_008410L752675 nM
Alexa Fluor 488 PhalloidinInvitrogen, RRID:SCR_008410A12379(1:500)
Vectashield mounting mediumVector Laboratories, RRID:SCR_000821VectorLabs: H-1000
Vectashield mounting medium with DAPIVector Laboratories, RRID:SCR_000821VectorLabs: H-1200
Halocarbon Oil 27Sigma-Aldrich, RRID:SCR_008988Sigma Aldrich: Cat# H8773
srpHemo-mrvathis paperCG8602 amplified from genome cloned into srpHemo plasmid
srpHemo-MFSD1this papermmMFSD1 amplified from dendritic cell cDNA library cloned into srpHemo plasmid
Mrva fwFly Primer BankqPCR; 5'TGTGCTTCGTGGGAGGTTTC
Mrva rvFly Primer BankqPCR; 5'GCAGGCAAAGATCAACTGACC
C1GalTA fwFly Primer BankqPCR; 5'TGCCAACAGTCTGCTAGGAAG
C1GalTA rvFly Primer BankqPCR: 5'CTGTGATGTGCATCGTTCACG
Ugalt fwFly Primer BankqPCR; 5'GCAAGGATGCCCAGAAGTTTG
Ugalt rvFly Primer BankqPCR; 5'GATATAGACCAGCGAGGGGAC
RpL32 fwFly Primer BankqPCR; 5'AGCATACAGGCCCAAGATCG
RpL32 rvFly Primer BankqPCR; 5'TGTTGTCGATACCCTTGGGC
Lectin staining kit #2EY LaboratoriesEYLabs:FLK-002
FIJIhttp://fiji.sc/
RRID:SCR_002285)
Imarishttp://www.bitplane.com/imaris/imaris, RRID:SCR_007370
Matlabhttps://www.mathworks.com/products/matlab.html,
RRID:SCR_001622
FlowJohttps://www.flowjo.com/RRID:SCR_008520
LaVision ImSpectorhttp://www.lavisionbiotec.com/,
RRID:SCR_015249
Proteome Discoverer 1.4https://www.thermofisher.com/order/
catalog/product/OPTON-30795, RRID:SCR_014477
LightCycler 480 softwarehttps://lifescience.roche.com/en_at/products/lightcycler14301-480
-software-version-15.html
GraphPad Prismhttps://www.graphpad.com/scientific-software/prism/
RRID:SCR_002798

Fly work

Flies were raised on food bought from IMBA (Vienna, Austria) which contained the standard recipe of agar, cornmeal, and molasses with the addition of 1.5% Nipagin. Adults were placed in cages in a Percival DR36VL incubator maintained at 29°C and 65% humidity; embryos were collected on standard plates prepared in house from apple juice, sugar, agar and Nipagin supplemented with yeast from Lesaffre (Marcq, France) on the plate surface. Embryo collections for fixation (7 hr collection) as well as live imaging (4.5 hr collection) were conducted at 29°C.

Fly Lines utilized

Request a detailed protocol

srpHemo-GAL4 was provided by K. Brückner (UCSF, USA) (Bruckner et al., 2004), UAS-CG8602::FLAG::HA (from K. VijayRaghavan National Centre for Biological Sciences, Tata Institute of Fundamental Research) (Guruharsha et al., 2011). The stocks w1118; minerva3102 (BDSC-17262), (pn1;; ry503Dr1P[Δ 2–3] (BDSC-1429), Df(3L)BSC117 (BDSC-8976), Oregon R (BDSC-2375), w-; P{w[+mC]=UAS mCherry.NLS}2;MKRS/Tm6b, Tb(1) (BDSC-38425), w-,P{UAS-Rab11-GFP}2 (BDSC-8506), y(1) sc[*] v(1); P{y[+t7.7] v[+t1.8]=TRiP .GL00069}attP2 (BDSC-35195), y(1) w[*]; Mi{y[+mDint2]=MIC}GlcAT-P[MI05251]/TM3, Sb(1) (BDSC-40779) were obtained from the Bloomington Drosophila Stock Centre, Bloomington, USA. The RNAi lines v60100, v110406, v2826, v101575 were obtained from the Vienna Drosophila Resource Center (VDRC), Vienna, Austria. Lines w-; P{w[+mC; srpHemo-3xmCherry}, w-; P{w[+mC; srpHemo-H2A::3xmCherry} were published previously (Gyoergy et al., 2018).

Exact genotype of Drosophila lines used in figures

Request a detailed protocol

Figure 1D-H: w-; +; srpHemo-3xmCherry. Figure 1I-K: Control: w- P(w+)UAS-dicer/w-; P{attP,y[+],w[3`]/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+. C1GalTA RNAi: w- P(w+)UAS-dicer2/w-; RNAi C1GalTA (v110406)/+; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+. Figure 1L: Control: w-; +; srpHemo-H2A::3xmCherry. C1GalLTA mutant: w-; C1GalTA2.1; srpHemo-H2A::3xmCherry. Figure 1M: Control: w-; srpHemo-H2A::3xmCherry. GlcAT-P mutant: w-; srpHemo-H2A::3xmCherry, Mi{MIC}GlcAT-PMI05251.

Figure 1—figure supplement 1A–L: w-; +; srpHemo-3xmCherry. Figure 1—figure supplement 1M, N, P: Control: w- UAS-Dicer2/w-; P{attP,y[+]w[3`]/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+. C1GalTA RNAi: w-UAS-Dicer2/w-; RNAi C1GalTA (v110406)/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+. Figure 1—figure supplement 1O: Control: w-; +; srpHemo-H2A::3xmCherry. C1GalTA mutant: w-; C1GalTA2.1; srpHemo-H2A::3xmCherry. Figure 1—figure supplement 1P: Control: w- UAS-Dicer2/w-; P{attP,y[+]w[3`]/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+. C1GalTA RNAi: w-UAS-Dicer2/w-; RNAi C1GalTA (v2826)/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+. Figure 1—figure supplement 1Q: Control: w-; srpHemo-H2A::3xmCherry. GlcAT-P mutant: w-; srpHemo-H2A::3xmCherry; Mi{MIC}GlcAT-PMI05251.

Figure 2A, B, D: w-; +; srpHemo-3xmCherry. Figure 2E, F, G: Control: w-; +; srpHemo-3xmCherry. CG8602 mutant: w-; +; srpHemo-3xmCherry,P{EP}CG86023102. Figure 2I: w-; srpHemo-Gal4; UAS-CG8602::FLAG::HA.

Figure 3A: w-; +; srpHemo-H2A::3xmCherry. Figure 3B: w-; +; srpHemo-H2A::3xmCherry, P{EP}CG86023102. Figure 3C: w-; srpHemo-CG8602; srpHemo-H2A::3xmCherry P{EP}CG86023102. Figure 3D: Control: w-; srpHemo-Gal4 UAS-mCherry::nls; +. CG8602 (Mrva) mutant: w-; srpHemo-Gal4 UAS-mCherry::nls; P{EP}CG86023102, Df cross: w-; srpHemo-Gal4 UAS-mCherry:nls; P{EP}CG86023102/Df(3L)BSC117. Rescue: w-; srpHemo-Gal4 UAS-mCherry:nls; UAS-CG8602::FLAG::HA P{EP}CG86023102. Precise excision: srpHemo-Gal4 UAS-mCherry:nls; P{EP}CG86023102Δ32. Figure 3E: Control: w- P(w+)UAS-dicer/+; +; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+. Mrva RNAi: w- UAS-dicer2/w-; RNAi CG8602 (v101575)/+; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+. Figure 3F: Control: w-; srpHemo-Gal4 UAS-mCherry::nls; +. Mrva mutant: w-; srpHemo-Gal4 UAS-mCherry::nls; P{EP}CG86023102. Figure 3G: Control: w-; +; srpHemo-3xmCherry. Mrva mutant: w-; +; srpHemo-3xmCherry P{EP}CG86023102. Cadherin Mrva double mutant: w-; shgP34; srpHemo-3xmCherry P{EP}CG86023102. Figure 3H: Control: w-; +; srpHemo-3xmCherry. Mrva mutant: w-; +; srpHemo-3xmCherry P{EP}CG86023102. Figure 3I-M: Control: w-; +; srpHemo-H2A::3xmCherry. Mrva mutant: w-; +; srpHemo-H2A::3xmCherry P{EP}CG86023102.

Figure 3-figure supplement 1A: Control: w-; +; srpHemo-H2A::3xmCherry. Mrva mutant: w-; +; srpHemo-H2A::3xmCherry P{EP}CG86023102. Rescue: w-; srp-CG8602; srpHemo-H2A::3xmCherry P{EP}CG86023102. Figure 3-figure supplement 1B, C, E: Control: w-; +; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+. Mrva RNAi: w-; RNAi CG8602 (v101575)/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+. Figure 3-figure supplement 1D, F-G: Control: w-; +; srpHemo-H2A::3xmCherry. Mrva mutant: w-; +; srpHemo-H2A::3xmCherry P{EP}CG86023102. Figure 3-figure supplement 1H-L: Control: w-; +; srpHemo-3xmCherry. Mrva mutant: w-; +; srpHemo-3xmCherry P{EP}CG86023102

Figure 4A-I: Control: w-; +, srpHemo-3xmCherry. Mrva mutant: w-; +, srpHemo-3xmCherry P{EP}CG86023102.

Figure 5A-B: Control: w-; +; srpHemo-3xmCherry. Qsox1 mutant: w-;P{SUPor-P}Qsox1KG04615; srpHemo-3xmCherry. Figure 5C: w/y,w[1118]; P{attP,y[+],w[3`]}/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+.Qsox1 RNAI: w-/y,w[1118]; v108288/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+. Figure 5D-G: Control: w-; +; srpHemo-H2A::3xmCherry. Qsox1 mutant: w-;P{SUPor-P}Qsox1KG04615; srpHemo-H2A::3xmCherry. Figure 5J: Control: w-; +; srpHemo-3xmCherry. Mrva mutant: w-; +; srpHemo-3xmCherry P{EP}CG86023102. Qsox1 mutant: w-; P{SUPor-P}Qsox1KG04615;srpHemo-3xmCherry.

Figure 5-figure supplement 1A-B: Control: w-; +; srpHemo-3xmCherry. Qsox1 mutant: w-;P{SUPor-P}Qsox1KG04615; srpHemo-3xmCherry. Figure 5-figure supplement 1C, F: w-; +; srpHemo-H2A::3xmCherry, w-; P{SUPor-P}Qsox1KG04615; srpHemo-H2A::3xmCherry. Figure 5-figure supplement 1D-E: Control: w-/y,w[1118]; P{attP,y[+],w[3`]}/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+. Qsox1 RNAi: w-/y,w[1118]; v108288/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+. Figure 5-figure supplement 1K-N: Control: w-; +; srpHemo-3xmCherry. Mrva mutant: w-; +; srpHemo-3xmCherry P{EP}CG86023102, Qsox1 mutant: w-; P{SUPor-P}Qsox1KG04615; srpHemo-3xmCherry.

Figure 6D: w-; srpHemo-MFSD1; srpHemo-H2A::3xmCherry P{EP}CG86023102. Figure 6E: Control: w-; +; srpHemo-H2A::3xmCherry. Mrva mutant: w-; +; srpHemo-H2A::3xmCherry P{EP}CG86023102. MFSD1 rescue: w-; srpHemo-MFSD1; srpHemo-H2A::3xmCherry P{EP}CG86023102. Figure 6F, G: Control: w-; +; srpHemo-3xmCherry. Mrva mutant: w-; +; srpHemo-3xmCherry P{EP}CG86023102. MFSD1 rescue: w-; srpHemo-MFSD1; srpHemo-3xmCherry P{EP}CG86023102.

Embryo fixation and immunohistochemistry

Request a detailed protocol

Embryos were collected on apple juice plates from between 6 and 8.5 hr at 29°C. Embryos were incubated in 50% Chlorox (DanClorix) for 5 min and washed. Embryos were fixed with 17% formaldehyde/heptane for 20 min followed by methanol or ethanol devitellinization except for T antigen analysis, when embryos were fixed in 4% paraformaldehyde/heptane. Fixed embryos were blocked in BBT (0.1M PBS + 0,1% TritonX-100 +0,1% BSA) for 2 hr at RT. Antibodies were used at the following dilutions: α-T antigen (Steentoft et al., 2011) 1:5, α-GFP (Aves Labs Inc., Tigard, Oregon) 1:500; α-LanA (Kumagai et al., 1997) (a gift from Stefan Baumgartner) 1:500; α-Vasa (Aruna et al., 2009) (DSHB, deposited by A. Sprading/D. Williams) 1:25; and incubated overnight at 4°C (GFP) or room temperature (T antigen, LanA). Afterwards, embryos were washed in BBT for 2 hr, incubated with secondary antibodies (Thermo Fisher Scientific, Waltham, Massachusetts, USA) at RT for 2 hr, and washed again for 2 hr. Vectashield (Vector Laboratories, Burlingame, USA) was then added. After overnight incubation in Vectashield at 4°C, embryos were mounted on a slide and imaged with a Zeiss Inverted LSM700 Confocal Microscope using a Plan-Apochromat 20X/0.8 Air Objective or a Plan-Apochromat 63X/1.4 Oil Objective.

Ovary dissection and immunostaining

Request a detailed protocol

3–5 day old females were fed with yeast for 2 days at 25°C. For ovary dissection, females were anesthetized using the FlyNap anesthetic kit (Carolina, Burlington, NC, USA) and further transferred to ice cold PBS in which ovaries were extracted with pre-cleaned forceps. Individual ovaries were fixed in 4% Paraformaldehyde/PBS at room temperature (RT) for 20 min with agitation. Three wash steps with PBS at RT for 10 min were performed and individual ovaries were incubated in PBS supplemented with 0.1% of Triton X-100 (PBT) for 10 min at RT to allow permeabilization of the tissue. Ovaries were incubated in phalloidin-A488 (Thermo Fisher) diluted in PBT (1:300) overnight at 4°C. After being washed with PBT and PBS, ovaries were mounted in Vectashield + DAPI (LifeTechnologies, Carlsbad, USA).

Fixed ovary image analysis for border cell migration

Request a detailed protocol

Ovaries were imaged as a Z-series (1 µm apart) with a Plan-Apochromat 20X/0.8 Air Objective on a Zeiss LSM700 inverted microscope. Images were acquired from stage 10 oocytes and maximum-intensity projections were created using ImageJ (NHI, USA). Border cells were identified by the clustered nuclei and their enriched actin staining. Border cell migration was quantified in the DAPI images as the percentage observed relative to the expected migration to the edge of the oocyte for these cells in stage 10 oocytes. Measurements were performed using ImageJ software (NIH, USA).

Lectin staining

View detailed protocol

Embryos were fixed with 10% formaldehyde/heptane and devitellinized with Ethanol. Blocking was conducted in BBT for 2 hr at room temperature. A FITC-labeled lectin kit #2 (EY laboratories, San Mateo, CA, USA) was utilized (table below summarizes abbreviations of used lectins). Each lectin was diluted to 1:25 and incubated with fixed embryos overnight at room temperature (RT). Embryos were washed in BBT for 2 hr at RT and Vectashield was added. After overnight incubation at 4°C, embryos were mounted on a slide and imaged with a Zeiss Inverted LSM700 Confocal Microscope using a Plan-Apochromat 63X/1.4 Oil Objective. Macrophages in late Stage 11 embryos were imaged at germband entry and evaluated by eye for enriched staining on macrophages compared to other tissues.

LectinPeanut agglutininUlex
europaeus
agglutinin		Wheat germ
agglutinin		Griffonia
simplicifolia
agglutinin I		Maclura
pomifera agglutinin		Griffonia simplicifolia
agglutinin II
AbbreviationPNAUEA-IWGAGS-IMPAGS-II
LectinSoybean agglutininDolichos biflorus agglutininConcanavalin AHelix pomatia agglutininLimulus poly-phenus agglutininBauhinia purpurea agglutinin
AbbreviationSBADBAConAHPALPABPA

Macrophage extraction

Request a detailed protocol

Embryos were bleached in 50% Chlorox in water for 5 min at RT. Stage late 11/early 12 embryos were lined up and then glued to 50 mm Dish No. 0 Coverslip, 14 mm Glass Diameter, Uncoated dish (Zeiss, Germany). Cells from the germband margin were extracted using a ES Blastocyte Injection Pipet (spiked, 20 μm inner diameter, 55 mm length; BioMedical Instruments, Germany). Extracted cells were placed in Schneider’s medium (Gibco, Dublin, Ireland) supplemented with 20% FBS (Sigma-Aldrich, Saint Louis, Missouri, USA).

Immunohistochemistry of extracted macrophages

Request a detailed protocol

Extracted macrophages were collected by centrifugation at 500 g for 5 min at room temperature. The cell pellet was resuspended in a small volume of Phospho-buffered saline (PBS) and smeared on a cover slip. The cell suspension was left to dry before cells were fixed with 4% paraformaldehyde in 0.1M Phosphate Buffer for 20 min at room temperature. Cells were washed 3 times in 0.1M PBS and permeabilized in 0.5% Triton-X 100 in PBS. Cells were blocked for 1 hr at room temperature in 20% Fetal Bovine Serum +0.25% Triton X-100 in PBS. Primary antibodies were diluted in blocking buffer: anti-HA (Roche, Basel, Switzerland) 1:50, anti-Golgin 84, 1:25, anti-Calnexin 99a 1:25, anti-Hrs.8.2 1:25 or anti-Rab7 1:25 all from DSHB (Riedel et al., 2016), and incubated for 1 hr at room temperature. Cells were then washed 5 times in blocking buffer. Secondary antibodies were diluted in blocking buffer: anti-rat 633 1:300, anti-mouse 488 1:300 (both from ThermoFisher Scientific, Waltham, Massachusetts, USA). Secondary antibodies were incubated for 1 hr at room temperature. Cells were washed 5 times in PBS + 0.1% Triton X-100 and mounted in VectaShield + DAPI (LifeTechnologies, Carlsbad, USA) utilized at 1:75.

S2 cell work

Request a detailed protocol

S2R+ cells (a gift from Frederico Mauri of the Knoblich laboratory at IMBA, Vienna) were grown in Schneider’s medium (Gibco) supplemented with 10% FBS (Gibco) and transfected with PTS1-GFP (a gift from Dr. McNew) and/or the srpHemo-CG8602::3xmCherry construct using Effectene Tranfection Reagent (Qiagen, Hilden, Germany) following the manufacturer’s protocol. Transfected S2R+ cells were grown on Poly-L-Lysine coated coverslips (ThermoFisher Scientific, Waltham, Massachusetts, USA) in complete Schneider’s medium (Gibco) supplemented with 10% FBS (Sigma-Aldrich, Saint Louis, Missouri, USA) and 1% Pen/Strep (Gibco) to a confluency of 60%. To visualize lysosomes, cells were incubated with Lysotracker 75 nM Green DND-26 (Invitrogen) in complete Schneider’s medium for 30 min at 25°C. Cells were washed in complete Schneider’s medium 3 times before imaging on an inverted LSM-700 (Zeiss). To visualize mitochondria, mitotracker Green FM (Invitrogen, Carlsbad, CA, USA) was diluted in prewarmed Schneider’s medium supplemented with 1% Pen/Strep to a concentration of 250 nM. Cells were incubated in the Mitotracker solution for 45 min at 25°C. Cells were then washed 3 times in complete Schneider’s medium before imaging.

To visualize Golgi, ER, early and late endosomes as well as the nucleus, S2R+ cells were transfected with MT-CG8602::FLAG::HA (DGRC: FMO06045) or MT-Qsox1::FLAG::HA (DGRC: FMO06379) with Effectene Tranfection Reagent (Qiagen) following the manufacturer’s protocol. 24 hr after transfection gene expression was induced by addition of 1 mM Cu2SO4 (Sigma) and cells were incubated for an additional 24 hr. Cells were then fixed in 4% PFA (Sigma) in 0.1M PB for 20 min at room temperature, permeabilized in 0.5% Triton X-100 (Sigma) in PBS for 15 min and blocked for 2 hr in 20% FBS (Sigma), 0.25% Triton X-100 in PBS at room temperature.

Cells were then stained with anti-HA antibody 1:50 (Roche) and either anti-Cnx99a (1:5), anti-Hrs 8.2 (1:5), anti-Golgin 84 (1:5), anti-Rab7 (1:5), anti- GMAP (1:50) or anti- Golgin 245 (1:50) (all antibodies from DSHB) (Riedel et al., 2016). Cells were washed in 20% FBS (Sigma), 0.25% Triton X-100 in PBS 5 times and then incubated with anti-rat Alexa Fluor 633 1:50 and either anti-mouse Alexa Fluor 488 or anti-goat Alexa Fluor 488 1:100 (Thermo Fisher) for 2 hr at room temperature. Cells were washed again 5 times and then mounted in Vectashield Mounting Medium +DAPI (Vector Laboratories) and imaged with Zeiss LSM 700 or 800 confocal microscopes. Quantitation of colocalization was performed as indicated below.

The cell line was routinely tested for Mycoplasm infection and found to be negative.

DNA isolation from single flies

Request a detailed protocol

Single male flies were frozen for at least 3 hr before grinding them in 100 mM Tris-HCl, 100 mM EDTA, 100 mM NaCL and 0.5% SDS. Lysates were incubated at 65°C for 30 min. Then 5M KAc and 6M LiCl were added at a ratio of 1:2.5 and lysates were incubated on ice for 10 min. Lysates were centrifuged for 15 min at 20,000xg, supernatant was isolated and mixed with Isopropanol. Lysates were centrifuged again for 15 min at 20.000xg, supernatant was discarded and the DNA pellet was washed in 70% EtOH and subsequently dissolved in ddH20.

FACS sorting

Request a detailed protocol

Embryos were collected for 1 hr and aged for an additional 5 hr, all at 29°C. Embryos collected from w- flies were processed in parallel and served as a negative control. Embryos were dissociated as described previously (Gyoergy et al., 2018). The cells were sorted using a FACS Aria III (BD) flow cytometer. Emission filters were 600LP, 610/20 and 502 LP, 510/50. Data were analyzed with FlowJo software (Tree Star). The cells from the dissociated negative control w- embryos were sorted to set a baseline plot.

qPCR

Request a detailed protocol

RNA was isolated from approximately 50,000 mCherry positive or mCherry negative FACS sorted macrophages using RNeasy Plus Micro Kit (Qiagen, Hilden, Germany) following manufacturer’s protocol. RNA was also isolated from 50 to 100 mg of ovaries (about 15–20 pairs of ovaries extracted as indicated above). Ovaries were homogenized with a pellet homogenizer (VWR, Radnor, USA) and plastic pestles (VWR, Radnor, USA) in 1 ml of Trizol (Thermo Fisher Scientific, Waltham, MA, USA) and centrifuged at 12,000xg for 5 min at 4°C. Further steps were according to the manufacturers protocol. The resulting RNA was used for cDNA synthesis using Sensiscript RT Kit (macrophages) or Omniscript (ovaries) (Qiagen, Hilden, Germany) and oligo dT primers. A Takyon qPCR Kit (Eurogentec, Liege, Belgium) was used to mix qPCR reactions based on the provided protocol. qPCR was run on a LightCycler 480 (Roche, Basel, Switzerland) and data were analyzed in the LightCycler 480 Software and Prism (GraphPad Software). Data are represented as relative expression to a housekeeping gene (2-Δct) or fold change in expression (2-ΔΔct). Primer sequences utilized for flies were obtained from the FlyPrimerBank (http://www.flyrnai.org/FlyPrimerBank). Minerva/CG8602: Fw pr TGTGCTTCGTGGGAGGTTTC, Rv pr GCAGGCAAAGATCAACTGACC. C1GalTA: Fw pr TGCCAACAGTCTGCTAGGAAG, Rv pr CTGTGATGTGCATCGTTCACG. Ugalt: Fw pr GCAAGGATGCCCAGAAGTTTG, Rv pr GATATAGACCAGCGAGGGGAC. RpL32: Fw pr AGCATACAGGCCCAAGATCG, Rv pr TGTTGTCGATACCCTTGGGC

Protein preps from embryos for western blots

Request a detailed protocol

Embryos were collected for 7 hr at 29°C, bleached and hand-picked for the correct stage. 50–200 embryos were smashed in RIPA buffer (150 mM NaCl, 0,5% Sodiumdeoxychalat, 0,1% SDS, 50 mM Tris, pH 8) with Protease inhibitor (Complete Mini, EDTA free, Roche, Basel, Switzerland) using a pellet homogenizer (VWR, Radnor, USA) and plastic pestles (VWR, Radnor, USA) and incubated on ice for 30 min. Afterwards, samples were centrifuged at 4°C, 16,000 g for 30 min and the supernatant was collected and used for experiments. The protein concentration was quantified using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific).

Western blots

Request a detailed protocol

30 μg of protein samples were loaded on a 4–15% Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad, Hercules, USA) and run at 100V for 80 min in 1x running buffer (25 mM Tris Base, 190 mM glycine and 0.1%SDS) followed by transfer onto Amersham Protran Premium 0.45 μm NC (GE Healthcare Lifescience, Little Chalfont, UK) or Amersham Hybond Low Fluorescence 0.2 μm PVDF (GE Healthcare Lifescience, Little Chalfont, UK) membrane using a wet transfer protocol with 25 mM Tris Base, 190 mM Glycine +20% MeOH at either 100 Volts for 60 min or 200mA for 90 min at Mini Trans-Blot Cell Module (Bio-Rad, Hercules, USA). Membranes were blocked in PBS-T (0.1% Triton X-100 in PBS) containing 2% BSA or Pierce Clear Milk Blocking Buffer (ThermoFisher Scientific) for 1 hr at RT. Primary antibodies were incubated overnight at 4°C at the following concentrations: α-T antigen (Copenhagen) 1:10, α-profilin (Verheyen and Cooley, 1994), DSHB) 1:50, anti-GFP (clone 2B6, Ogris lab, MFPL), anti-GAPDH (ab181603, Abcam, Cambridge, UK). Afterwards, blots were washed 3x for 5 min in blocking solution and incubated with Goat anti Mouse IgG (H/L):HRP (Bio-Rad, Hercules, USA) or goat-anti-rabbit IgG (H + L)-HRP (Bio-Rad, Hercules, USA) at 1:5 000–10,000 for 1–2 hr at room temperature. Blots were washed 2 × 5 min in blocking solution and 1 × 5 min with PBS-T. Blots were developed using SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific, Waltham, Massachusetts, USA) according to manufacturer’s instructions. Chemiluminescent signal was detected using the Amersham Imager 600 (GE Healthcare Lifescience) or VersaDoc (Bio-Rad). Images were processed with ImageJ.

Western blot analysis of S2R+ supernatant

Request a detailed protocol

S2R+ cells were transfected as described previously with srpGal4 UAS-Qsox1::FLAG::HA. 2 days post-transfection, medium was removed and cells were washed with PBS. Afterwards, serum-free S2 medium was added and incubated for approximately 40 hr. Afterwards, supernatant was collected and concentrated using Amicon Ultra-4 10K Centrifugal Filter Device (Merck, Kenilworth, New Jersey, United States) to gain 80 μl of concentrated supernatant. 20 μl of supernatant was loaded on gel and analyzed by anti-HA (1:200, Roche). Images were processed with ImageJ.

Time-lapse imaging, tracking, speed, persistence and germband entry analysis

Request a detailed protocol

Embryos were dechorionated in 50% bleach for 5 min, washed with water, and mounted in halocarbon oil 27 (Sigma-Aldrich, Saint Louis, Missouri, USA) between a coverslip and an oxygen permeable membrane (YSI). The anterior dorsolateral region of the embryo was imaged on an inverted multiphoton microscope (TrimScope II, LaVision) equipped with a W Plan-Apochromat 40X/1.4 oil immersion objective (Olympus). mCherry was imaged at 1100 nm excitation wavelengths, using a Ti-Sapphire femtosecond laser system (Coherent Chameleon Ultra) combined with optical parametric oscillator technology (Coherent Chameleon Compact OPO). Excitation intensity profiles were adjusted to tissue penetration depth and Z-sectioning for imaging was set at 1 µm for tracking and segmentation respectively. For long-term imaging, movies were acquired for 132–277 min with a frame rate of 40 s. All embryos were imaged with a temperature control unit set to 28.5°C.

Images acquired from multiphoton microscopy were initially processed with InSpector software (LaVision Bio Tec) to compile channels from the imaging data, and the exported files were further processed using Imaris software (Bitplane) to visualize the recorded channels in 3D. Macrophage speed and persistence were calculated by using embryos in which the macrophage nuclei were labeled with srpHemo-H2A::3XmCherry (Gyoergy et al., 2018). The movie from each imaged embryo was rotated and aligned along the AP axis for tracking analysis. Increasing the gain allowed determination of germband position from the autofluorescence of the yolk. Movies for vnc analysis were analyzed for 2 hr from the time point that cells started to dive into the channels to reach the outer vnc. Macrophage nuclei were extracted using the spot detection function and nuclei positions in xyz-dimensions were determined for each time point and used for further quantitative analysis. Cell speeds and directionalities were calculated in Matlab (The MathWorks Inc., Natick, Massachusetts, USA) from single cell positions in 3D for each time frame measured in Imaris (Bitplane). Instantaneous velocities from single cell trajectories were averaged to obtain a mean instantaneous velocity value over the course of measurement. To calculate directionality values, single cell trajectories were split into segments of equal length (10 frames) and calculated via a sliding window as the ratio of the distance between the macrophage start-to-end location over the entire summed distance covered by the macrophage between successive frames in a segment. Calculated directionality values were averaged over all segments in a single trajectory and all trajectories were averaged to obtain a mean directionality value for the duration of measurement, with 0 being the lowest and one the maximum directionality. To estimate the time for entry into the germband, we increased the gain to visualize the germband position from the autofluorescence of the yolk. We assessed the time point when the first macrophage nucleus reached the edge of the germband (taken as T0) and the time point when the first cell nucleus was just within the germband (taken as T1). T1-T0 was defined as the time for macrophage entry.

Fixed embryo image analysis for T antigen levels

Request a detailed protocol

Embryos were imaged with Plan-Apochromat 63X/1.4 Oil Objective on a Zeiss LSM700 inverted. 10 µm stacks (0.5 µm intervals) were taken for properly staged and oriented embryos, starting 10 µm deep in the tissue. These images were converted into Z-stacks in Fiji. ROIs were drawn around macrophages (signal), copied to tissue close by without macrophages (background) and the average intensity in the green channel of each ROI was measured. For each pair of ROIs background was subtracted from signal individually. The average signal from control ROIs from one imaging day and staining was calculated and all data points from control, mutant and rescue from the same set was divided by this value. This way we introduced an artificial value called Arbitrary Unit (AU) that makes it possible to compare all the data with each other, even if they come from different imaging days when the imaging laser may have a different strength or from different sets of staining. Analysis was done on anonymized samples.

Macrophage cell counting

Request a detailed protocol

Transmitted light images of the embryos were used to measure the position of the germband to determine the stages for analysis. The extent of germband retraction away from the anterior along with the presence of segmentation was used to classify embryos. Embryos with germband retraction of between 29–31% were assigned to late Stage 11. Those with 29–41% retraction (early Stage 12) were analyzed for the number of macrophages that had entered the germband and those with 50–75% retraction (late Stage 12) for the number along the ventral nerve cord (vnc), and in the whole embryo. Macrophages were visualized using confocal microscopy with a Z-resolution of 3 μm and the number of macrophages within the germband or the segments of vnc was calculated in individual slices (and then aggregated) using the Cell Counter plugin in FIJI.

To check that this staging allows embryos from the control and mrva3102 mutant to be from the same time during development, embryos were collected for 30 min and then imaged for a further 10 hr using a Nikon-Eclipse Wide field microscope with a Plan-Apochromat 20X/0.5 DIC water Immersion Objective. Bright field images were taken every 5 min, and the timing of the start of the movies was aligned based on when cellularization occurred. We found no significant difference in when germband retraction begins (269.6 ± 9 min in control and 267.1 ± 3 min in mrva3102, p=0.75) or in when the germband retracts to 41% (300 ± 9 min for control, 311 ± 5 min in mrva3102, p=0.23), or in when the germband retraction is complete (386.5 ± 10 min for control, 401.6 ± 8 min for mrva3102, p=0.75). n = 10 embryos for control and 25 embryos for mrva3102.

Cloning

Standard molecular biology methods were used and all constructs were sequenced by Eurofins before injection into flies. Restriction enzymes BSiWI, and AscI were obtained from New England Biolabs, Ipswich, Massasuchetts, USA (Frankfurt, Germany). PCR amplifications were performed with GoTaq G2 DNA polymerase (Promega, Madison, USA) using a peqSTAR 2X PCR machine from PEQLAB, (Erlangen, Germany). All Infusion cloning was conducted using an Infusion HD Cloning kit obtained from Clontech’s European distributor (see above); relevant oligos were chosen using the Infusion primer Tool at the Clontech website.

Construction of srpHemo-minerva

Request a detailed protocol

A 1467 bp fragment containing the Minerva (CG8602) ORF was amplified from the UAS-CG8602:FLAG:HA construct (DGRC) using primers Fw GAAGCTTCTGCAAGGATGGCGCGCGAGGACGAGGAAC, Rv CGGTGCCTAGGCGCGCTATTCAAAGTTCTGATAATTCTCG. The fragment was cloned into the srpHemo plasmid (a gift from Katja Brückner, (Bruckner et al., 2004)) after its linearization with AscI, using an Infusion HD cloning kit.

Construction of srpHemo-MFSD1

Request a detailed protocol

A 1765 bp fragment containing the MFSD1 ORF was amplified from cDNA prepared from dendritic cells (a gift from M. Sixt's lab) with Fw primer TAGAAGCTTCTGCAACTTTGCTTCCTGCTCCGTTC, Rv primer ATGTGCCTAGGCGCGAAGGAAAGGCTTCATCCGCA). The fragment was cloned into the srpHemo plasmid (a gift from Katja Brückner, (Bruckner et al., 2004) using an Infusion HD cloning kit (Clontech) after its linearization with AscI (NEB).

Construction of srpHemo-mrva::3xmCherry

Request a detailed protocol

Minerva (CG8602) was amplified from a DNA prep from Oregon R flies (Fw primer: AGAGAAGCTTCGTACGCGACAACCCTGCTCTACAGAG; Rv primer CGACCTGCAGCGTACGACCCGATCCTTCAAAGTTCTG). The vector, PCasper4 containing a 3xmCherry construct under the control of the srpHemo promoter (Gyoergy et al., 2018), was digested with BsiWI according to the manufacturer’s protocol. The vector and insert were homologously recombined using the In-Fusion HD Cloning Kit.

Generation of pInducer20-MFSD1-eGFP constructs

Request a detailed protocol

For C-terminal tagging MFSD1 was PCR amplified from cDNA prepared from dendritic cells (a gift from M. Sixt lab) (Fw primer:GATCTCGAGATGGAGGACGAGGATG; Rv primer: CGACCGGTAACTCTGGATGAGAGAGC) and digested with XhoI and AgeI (both New England Biolabs, Ipswich, Massasuchetts, USA). This MFSD1 fragment was cloned into XhoI/AgeI digested peGFP-N1 (Addgene, Cambridge, Massachusetts, USA). C-terminally eGFP tagged MFSD1 was further PCR amplified (Fw primer: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGAGGACGAGGAT; Rv primer: GGGGACCACTTTGTACAAGAAAGCTGGGTATTACTTGTACAGCTC). This fragment was cloned using Gateway BP Clonase II Enzyme mix and Gateway LR Clonase II Enzyme Mix (ThermoFisher Scientific, Waltham, Massachusetts, USA) via donor vector pDonR211 into the final Doxycyclin inducible expression vector pInducer20 (Meerbrey et al., 2011) according to the manufacturer’s instructions. pInducer20-MFSD1-eGFP was amplified in stbl3 bacteria (ThermoFisher Scientific, Waltham, Massachusetts, USA).

Precise excision

Request a detailed protocol

mrva3102 flies which contain the 3102 P element insert in the 5’ region of CG8602 were crossed to a line expressing transposase (BL-1429: pn1; ry503Dr1P[Δ 2–3]). To allow excision of the P Element, males from the F1 generation containing both the P element and the transposase, were crossed to virgins with the genotype Sp/Cyo; PrDr/TM3Ser (gift from Lehmann lab). In the F2 generation white eyed males were picked and singly crossed to Sp/Cyo; PrDr/TM3Ser virgins.

LanA quantification

Request a detailed protocol

Images were taken with a Z-resolution of 0.5 μm from the head of late stage 12 embryos using a Zeiss LSM800 confocal microscope and a 40x/1.4 Oil DIC objective. A 4 μm long line was drawn over a macrophage with the middle of the line located approximately at the edge of the cell. mCherry and LanA (488) intensities were measured using the Multichannel Plot Profile Plugin in Fiji. Three lines were drawn on each cell to catch the variability of secretion. Only cells standing alone or in small groups that had at least some small visible amount of extracellular LanA were analyzed. From each embryo, 20 cells were analyzed. Images were anonymized before quantification.

Mammalian cell culture

Request a detailed protocol

MC-38 colon carcinoma cells, 4T1 breast carcinoma (ATCC, CRL-2539), Lewis Lung carcinoma LLC1 (ATCC, CRL-1642) and B16-BL6 melanoma (NCI-DTP; B16BL-6) (all gifts from the Borsig lab) were kept in DMEM supplemented with 10% FCS (Sigma-Aldrich, Saint Louis, Missouri, USA), Non-essential Amino Acids, and Na-Pyruvate (Thermo Fisher Scientific, Waltham, Massachusetts, USA). All cells were kept in a humidified incubator at 37°C with 5% CO2. Cells were infected with lentiviral particles containing pInducer20-MFSD1-eGFP. Expression of MFSD1-eGFP was induced with 20 ng/ml (for MC-38) and 100 ng/ml (for 4T1, LLC, B16-BL6) of Doxycycline for 24 hr prior subsequent analysis. Cell lines were routinely tested for Mycoplasm infection and found to be negative. The identity of the cell lines was confirmed by STR analysis by the cell bank from which they were obtained.

Mammalian cell lysis

Request a detailed protocol

Cells were lysed in alysis buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with a protease inhibitor cocktail (Complete, Roche, Basel, Switzerland) for 20 min on ice, followed by centrifugation at 14,000x g, 4°C for 5 min. The protein lysates were stored at −80°C. Protein concentration was determined with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).

Mammalian cell immunofluorescence

Request a detailed protocol

Cells were fixed with 4% formaldehyde (Thermo Fisher Scientific) in PBS for 15 min at room-temperature. Cells were washed three times with PBS followed by blocking and permeabilization with 1% BSA (Sigma-Aldrich, Saint Louis, Missouri, USA)/0.3% Triton X-100 in PBS for 1 hr. Antibodies were diluted in blocking/permeabilization buffer and incubated for 2 hr at room temperature. Primary antibodies used were: anti-GFP (clone 5G4, Ogris lab, MFPL), anti-GRASP65 (Thermo Fisher, PA3-910), anti-Rab5 (Cell Signaling Technology, #C8B1), anti-Rab7 (Cell Signaling Technology, #D95F2) and anti-LAMP1 (Abcam, Cambridge, UK, #ab24170). Cells were washed three times with PBS-Tween20 (0.05%) for 5 min each, followed by secondary antibody incubation in blocking/permeabilization buffer for 1 hr at room-temperature. Secondary antibodies used were: goat anti-mouse IgG (H + L) Alexa Fluor 488 (Thermo Fisher A11001), goat anti-rabbit IgG (H + L) Alexa Fluor 555 (Thermo Fisher, A21428), Cells were counterstained with DAPI (Thermo Fisher) for 10 min in PBS. Cells were mounted with ProLong Gold Antifade Mountant (Thermo Fisher #P36930). Images were acquired using a Plan-Apochromat 40x/1.4 Oil DIC objective M27 on a Zeiss LSM880 confocal microscope. Pictures were processed with ImageJ.

Quantification of secretory pathway marker colocalization with Mrva, MFSD1 and Qsox1

Request a detailed protocol

Colocalization analysis was performed by ImageJ’s (NIH) Coloc two plugin and determined with the pixel intensity spatial correlation analysis (Pearson’s correlation coefficient).

Embryonic protein prep for glycoproteomics

Request a detailed protocol

150 mg fly embryos were homogenized in 2 ml 0.1% RapiGest, 50 mM ammonium bicarbonate using a dounce homogenizer. The lysed material was left on ice for 40 min with occasional vortexing followed by probe sonication (5 s sonication, 5 s pause, 6 cycles at 60% amplitude). The lysate was cleared by centrifugation (1,000 × g for 10 min). The cleared lysate was heated at 80°C, 10 min followed by reduction with 5 mM dithiothreitol (DTT) at 60°C, 30 min and alkylation with 10 mM iodoacetamide at room temperature (RT) for 30 min before overnight (ON) digestion at 37°C with 25 µg trypsin (Roche). The tryptic digests were labeled with dimethyl stable isotopes as described (Boersema et al., 2009). The digests were acidified with 12 µL trifluoroacetic acid (TFA), 37°C, 20 min and cleared by centrifugation at 10,000 g, 10 min. The cleared acidified digests were loaded onto equilibrated SepPak C18 cartridges (Waters) followed by 3 × CV 0.1% TFA wash. Digests were labeled on the column by adding 5 mL 30 mM NaBH3CN and 0.2% formaldehyde (COH2) in 50 mM sodium phosphate buffer pH 7.5 (Light, mrva3102), or 30 mM NaBH3CN and 0.2% deuterated formaldehyde (COD2) in 50 mM sodium phosphate buffer pH 7.5 (Medium, control). Columns were washed using 3 CV 0.1% FA and eluted with 0.5 mL 50% MeOH in 0.1% FA. The eluates were mixed in a 1:1 ratio, concentrated by evaporation, and resuspended in Jacalin loading buffer (175 mM Tris-HCl, pH 7.4) Glycopeptides were separated from non-glycosylated peptides by Lectin Weak Affinity Chromatography (LWAC) using a 2.8 m column packed in-house with Jacalin-conjugated agarose beads. The column was washed with 10 CVs Jacalin loading buffer (100 µL/min) before elution with Jacalin elution buffer (175 mM Tris- HCl, pH 7.4, 0.8M galactose) 4 CVs, 1 mL fractions. The glycopeptide-containing fractions were purified by in-house packed Stage tips (Empore disk-C18, 3M).

Quantitative O-glycoproteomic strategy

Request a detailed protocol

The glycopeptide quantification based on M/L isotope labeled doublet ratios was evaluated to estimate a meaningful cut-off ratio for substantial changes (Schjoldager et al., 2015). The labeled glycopeptides produced doublets with varying ratios of the isotopic ions as well as a significant number of single precursor ions without evidence of ion pairs. Labeled samples from control srpHemo-3xmCherry embryos and mrva3102 srpHemo-3xmCherry mutant embryos were mixed 1:1 and subjected to LWAC glycopeptide enrichment. The distribution of labeled peptides from the LWAC flow-through showed that the quantitated peptide M/L ratios were normally distributed with 99.7% falling within ±0.55 (Log10). We selected doublets with less/more than ±0.55(Log10) value as candidates for isoform-specific O-glycosylation events.

Mass spectrometry

Request a detailed protocol

EASY-nLC 1000 UHPLC (Thermo Scientific) interfaced via nanoSpray Flex ion source to an -Orbitrap Fusion mass spectrometer (Thermo Scientific) was used for the glycoproteomic study. A precursor MS1 scan (m/z 350–1,700) of intact peptides was acquired in the Orbitrap at a nominal resolution setting of 120,000. The five most abundant multiply charged precursor ions in the MS1 spectrum at a minimum MS1 signal threshold of 50,000 were triggered for sequential Orbitrap HCD-MS2 and ETD-MS2 (m/z of 100–2,000). MS2 spectra were acquired at a resolution of 50,000. Activation times were 30 and 200 ms for HCD and ETD fragmentation, respectively; isolation width was four mass units, and one microscan was collected for each spectrum. Automatic gain control targets were 1,000,000 ions for Orbitrap MS1 and 100,000 for MS2 scans. Supplemental activation (20%) of the charge-reduced species was used in the ETD analysis to improve fragmentation. Dynamic exclusion for 60 s was used to prevent repeated analysis of the same components. Polysiloxane ions at m/z 445.12003 were used as a lock mass in all runs. The mass spectrometry glycoproteomics data have been deposited to the ProteomeXchange Consortium (Vizcaíno et al., 2014) via the PRIDE partner repository with the dataset identifier PXD011045.

Mass spectrometry data analysis

Request a detailed protocol

Data processing was performed using Proteome Discoverer 1.4 software (Thermo Scientific) using Sequest HT Node as previously described (Schjoldager et al., 2015).

Briefly, all spectra were initially searched with full cleavage specificity, filtered according to the confidence level (medium, low and unassigned) and further searched with the semi-specific enzymatic cleavage. In all cases the precursor mass tolerance was set to six ppm and fragment ion mass tolerance to 20 mmu. Carbamidomethylation on cysteine residues was used as a fixed modification. Methionine oxidation as well as HexNAc and HexHexNAc attachment to serine, threonine and tyrosine were used as variable modifications for MS2 data. All spectra were searched against a concatenated forward/reverse Drosophila melanogaster-specific database (UniProt, March 2018, containing 39034 entries with 3494 canonical reviewed entries) using a target false discovery rate (FDR) of 1%. FDR was calculated using target decoy PSM validator node. The resulting list was filtered to include only peptides with glycosylation as a modification. Glycopeptide M/L ratios were determined using dimethyl 2plex method as previously described (Schjoldager et al., 2015)

Statistics and repeatability

Request a detailed protocol

Statistical tests as well as the number of embryos/cells assessed are listed in the Figure legends. All statistical analyses were performed using GraphPad Prism and significance was determined using a 95% confidence interval. Data points from individual experiments/embryos were pooled to estimate mean and standard error of the mean. Sample size refers to biological replicates. No statistical method was used to predetermine sample size and the experiments were not randomized. For major questions, data were collected and analyzed masked. Normality was evaluated by D’Agostino and Pearson or Shapiro-Wilk normality test. Unpaired t-test or Mann-Whitney test was used to calculate the significance in differences between two groups and One-Way Anova followed by Tukey post-test or Kruskal-Wallis test followed by Conover or Dunn’s post-test for multiple comparisons.

All measurements were performed in 3–38 embryos and at least 37 oocytes. Representative images shown in Figure 1E–G,I, Figure 2F,I, Figure 3A–C, Figure 5A, Figure 6B,D and G and Figure 2—figure supplement 1B-J, Figure 3—figure supplement 1B,H,K, Figure 5—figure supplement 1G, K were from separate experiments repeated 3 to 6 times. The stainings underlying Figure 1—figure supplement 1A-M, Figures 2Hand Figure 6-figure supplement 1C-F are from separate experiments that were repeated at least twice. Stills shown in Figure 3I,L and Figure 5D are representative images from two-photon movies, which were repeated at least 3 times.

Data availability

Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD011045.

The following data sets were generated
    1. Valoskova K
    2. Biebl J
    3. Larsen ISB
    4. Vakrushev SY
    5. Clausen H
    6. Siekhaus DE
    (2019) ProteomeXchange Consortium
    ID PXD011045. T and Tn antigen glycoproteomics of early St 12 Drosophila embryos, wild type and mrva mutant.
    http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD011045

References

    1. Aebi M
    (2013) N-linked protein glycosylation in the ER
    Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research 1833:2430–2437.
    https://doi.org/10.1016/j.bbamcr.2013.04.001
  21. Book
    1. Campos-Ortega JA
    2. Hartenstein V
    (1997)
    The Embryonic Development of Drosophila Melanogaster
    Berlin, Heidelberg: Springer Berlin Heidelberg.
    1. Cao B
    2. Yang L
    3. Rong W
    4. Feng L
    5. Han N
    6. Zhang K
    7. Cheng S
    8. Wu J
    9. Xiao T
    10. Gao Y
    (2015)
    Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma
    International Journal of Clinical and Experimental Pathology 8:16046–16054.
    1. Hofman K
    2. Stoffel W
    (1993)
    TMbase-A database of membrane spanning proteins segments
    Journal of Biological Chemistry 374:.
    1. Li S
    2. Liu P
    3. Xi L
    4. Jiang X
    5. Wu M
    6. Deng D
    7. Wei J
    8. Zhu T
    9. Zhou L
    10. Wang S
    11. Xu G
    12. Meng L
    13. Zhou J
    14. Ma D
    (2008)
    Expression of TMEM87B interacting with the human papillomavirus type 18 E6 oncogene in the hela cDNA library by a yeast two-hybrid system
    Oncology Reports 20:421–427.
    1. Lin YR
    2. Reddy BV
    3. Irvine KD
    (2008) Requirement for a core 1 galactosyltransferase in the Drosophila nervous system
    Developmental Dynamics : An Official Publication of the American Association of Anatomists 237:3703–3714.
    https://doi.org/10.1002/dvdy.21775
    1. MacLean GD
    2. Longenecker BM
    (1991)
    Clinical significance of the Thomsen-Friedenreich antigen
    Seminars in Cancer Biology 2:433–439.
    1. Orntoft TF
    2. Mors NP
    3. Eriksen G
    4. Jacobsen NO
    5. Poulsen HS
    (1985)
    Comparative immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and morphologically abnormal mucosa
    Cancer Research 45:447–452.
    1. Pierce GB
    (1974)
    Neoplasms, differentiations and mutations
    The American Journal of Pathology 77:103–118.
    1. Springer GF
    2. Desai PR
    3. Banatwala I
    (1975)
    Blood group MN antigens and precursors in normal and malignant human breast glandular tissue
    Journal of the National Cancer Institute 54:335–339.
  127. Book
    1. Stanley P
    2. Schachter H
    3. Taniguchi N
    (2009)
    N-Glycans, Essentials of Glycobiology
    Cold Spring Harbor Laboratory Press.
    1. Stojadinovic A
    2. Hooke JA
    3. Shriver CD
    4. Nissan A
    5. Kovatich AJ
    6. Kao TC
    7. Ponniah S
    8. Peoples GE
    9. Moroni M
    (2007)
    HYOU1/Orp150 expression in breast cancer
    Medical Science Monitor : International Medical Journal of Experimental and Clinical Research 13:231–239.
    1. Summers JL
    2. Coon JS
    3. Ward RM
    4. Falor WH
    5. Miller AW
    6. Weinstein RS
    (1983)
    Prognosis in carcinoma of the urinary bladder based upon tissue blood group abh and Thomsen-Friedenreich antigen status and karyotype of the initial tumor
    Cancer Research 43:934–939.
    1. Verheyen EM
    2. Cooley L
    (1994)
    Profilin mutations disrupt multiple actin-dependent processes during Drosophila development
    Development 120:717–728.

Article and author information

Author details

  1. Katarina Valoskova

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Conceptualization, Formal analysis, Funding acquisition, Investigation, Visualization, Writing—original draft, Writing—review and editing
    Contributed equally with
    Julia Biebl
    Competing interests
    No competing interests declared

  2. Julia Biebl

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Conceptualization, Formal analysis, Investigation, Visualization
    Contributed equally with
    Katarina Valoskova
    Competing interests
    No competing interests declared

  3. Marko Roblek

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Conceptualization, Investigation, Writing—review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9588-1389

  4. Shamsi Emtenani

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Formal analysis, Visualization
    Competing interests
    No competing interests declared

  5. Attila Gyoergy

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Resources, Visualization
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1819-198X

  6. Michaela Misova

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Investigation, Writing—review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2427-6856

  7. Aparna Ratheesh

    1. Institute of Science and Technology Austria, Klosterneuburg, Austria
    2. Centre for Mechanochemical Cell Biology and Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom
    Contribution
    Formal analysis, Visualization, Writing—review and editing, Funding acquisition
    Competing interests
    No competing interests declared

  8. Patricia Reis-Rodrigues

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Investigation, Visualization
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1681-508X

  9. Kateryna Shkarina

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Present address
    Department of Biochemistry, The University of Lausanne, Epalinges, Switzerland
    Contribution
    Investigation, Writing—review and editing
    Competing interests
    No competing interests declared

  10. Ida Signe Bohse Larsen

    Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Contribution
    Methodology
    Competing interests
    No competing interests declared

  11. Sergey Y Vakhrushev

    Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Contribution
    Data curation, Formal analysis, Methodology
    Competing interests
    No competing interests declared

  12. Henrik Clausen

    Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Contribution
    Conceptualization, Supervision, Project administration, Writing—review and editing, Funding acquisition
    Competing interests
    No competing interests declared

  13. Daria E Siekhaus

    Institute of Science and Technology Austria, Klosterneuburg, Austria
    Contribution
    Conceptualization, Supervision, Funding acquisition, Visualization, Writing—original draft, Project administration
    For correspondence
    daria.siekhaus@ist.ac.at
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8323-8353

Funding

Austrian Academy of Sciences

  • Katarina Valoskova

NO Forschungs und Bildungsges.m.b.H.

  • Marko Roblek

Horizon 2020 Framework Programme

  • Michaela Misova
  • Patricia Reis-Rodrigues

Austrian Science Fund (DASI_FWF01_P29638S)

  • Aparna Ratheesh

H2020 Marie Skłodowska-Curie Actions (IIF GA-2012-32950 BB: DICJI)

  • Aparna Ratheesh

Novo Nordisk Foundation

  • Sergey Y Vakhrushev
  • Henrik Clausen

Lundbeck Foundation

  • Sergey Y Vakhrushev
  • Henrik Clausen

Danish National Research Foundation (DNRF107)

  • Sergey Y Vakhrushev
  • Henrik Clausen

H2020 Marie Skłodowska-Curie Actions (CIG 334077/IRTIM)

  • Daria E Siekhaus

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank the following for their contributions: Dr. McNew and the Drosophila Genomics Resource Center supported by NIH grant 2P40OD010949-10A1 for plasmids, F Mauri, J Knöblich, and L Borsig for cell lines, K Brückner, M Sixt and the Sixt lab for helpful advice, KB, P Duchek, M Poukkula, K VijayRaghavan, and the Bloomington Drosophila Stock Center supported by NIH grant P40OD018537 and the Vienna Drosophila Resource Center for fly stocks. E Ogris, S Baumgartner and J Brennecke for gifts of antibodies, L Cooley, S Munro, A Spradling and D Williams for contributing the antibodies produced by the Developmental Studies Hybridoma Bank, which was created by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH, and is maintained at the University of Iowa. We thank the Life Scientific Service Units at IST Austria for technical support and assistance with microscopy and FACS analysis, and J Friml, C Guet, T Hurd and P Rangan for comments on the manuscript. KV was supported by a DOC fellowship from the Austrian Academy of Sciences. AG and AR were supported by the Austrian Science Fund (FWF) grant DASI_FWF01_P29638S, DES by Marie Curie CIG 334077/IRTIM, and AR also by Marie Curie IIF GA-2012–32950 BB: DICJI. MR was supported by the NO Forschungs und BildungsgesmbH. MM and PR received funding from the European Union’s Horizon 2020 research and Innovation programme under the Marie Sklodowska-Curie Grant Agreement No. 665385. SV and HC received funding from the Lundbeck Foundation, the Novo Nordisk Foundation, and the Danish Research Foundation (DNRF107). We are deeply grateful to R Lehmann in whose lab the work that served as the foundation for this project began.

Copyright

© 2019, Valoskova et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,170
    views
  • 362
    downloads
  • 24
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Katarina Valoskova
  2. Julia Biebl
  3. Marko Roblek
  4. Shamsi Emtenani
  5. Attila Gyoergy
  6. Michaela Misova
  7. Aparna Ratheesh
  8. Patricia Reis-Rodrigues
  9. Kateryna Shkarina
  10. Ida Signe Bohse Larsen
  11. Sergey Y Vakhrushev
  12. Henrik Clausen
  13. Daria E Siekhaus
(2019)
A conserved major facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue invasion
eLife 8:e41801.
https://doi.org/10.7554/eLife.41801

Share this article

https://doi.org/10.7554/eLife.41801

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Genetics and Genomics

    Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

    Rebecca Warfvinge, Linda Geironson Ulfsson ... Göran Karlsson
    Research Article

    The advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI-insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment and are imperative for disease progression as well as recurrence during treatment-free remission (TFR). Here, we have generated high-resolution single-cell multiomics maps from CML patients at diagnosis, retrospectively stratified by BCR::ABL1IS (%) following 12 months of TKI therapy. Simultaneous measurement of global gene expression profiles together with >40 surface markers from the same cells revealed that each patient harbored a unique composition of stem and progenitor cells at diagnosis. The patients with treatment failure after 12 months of therapy had a markedly higher abundance of molecularly defined primitive cells at diagnosis compared to the optimal responders. The multiomic feature landscape enabled visualization of the primitive fraction as a mixture of molecularly distinct BCR::ABL1+ LSCs and BCR::ABL1-hematopoietic stem cells (HSCs) in variable ratio across patients, and guided their prospective isolation by a combination of CD26 and CD35 cell surface markers. We for the first time show that BCR::ABL1+ LSCs and BCR::ABL1- HSCs can be distinctly separated as CD26+CD35- and CD26-CD35+, respectively. In addition, we found the ratio of LSC/HSC to be higher in patients with prospective treatment failure compared to optimal responders, at diagnosis as well as following 3 months of TKI therapy. Collectively, this data builds a framework for understanding therapy response and adapting treatment by devising strategies to extinguish or suppress TKI-insensitive LSCs.

    1. Cancer Biology
    2. Genetics and Genomics

    Cancer: Predicting drug resistance

    Nicole S Arellano, Shannon E Elf
    Insight

    A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

    1. Cancer Biology
    2. Cell Biology

    Actin networks modulate heterogeneous NF-κB dynamics in response to TNFα

    Francesca Butera, Julia E Sero ... Chris Bakal
    Research Article Updated

    The canonical NF-κB transcription factor RELA is a master regulator of immune and stress responses and is upregulated in pancreatic ductal adenocardinoma (PDAC) tumours. In this study, we characterised previously unexplored endogenous RELA-GFP dynamics in PDAC cell lines through live single-cell imaging. Our observations revealed that TNFα stimulation induces rapid, sustained, and non-oscillatory nuclear translocation of RELA. Through Bayesian analysis of single-cell datasets with variation in nuclear RELA, we predicted that RELA heterogeneity in PDAC cell lines is dependent on F-actin dynamics. RNA-seq analysis identified distinct clusters of RELA-regulated gene expression in PDAC cells, including TNFα-induced RELA upregulation of the actin regulators NUAK2 and ARHGAP31. Further, siRNA-mediated depletion of ARHGAP31 and NUAK2 altered TNFα-stimulated nuclear RELA dynamics in PDAC cells, establishing a novel negative feedback loop that regulates RELA activation by TNFα. Additionally, we characterised the NF-κB pathway in PDAC cells, identifying how NF-κB/IκB proteins genetically and physically interact with RELA in the absence or presence of TNFα. Taken together, we provide computational and experimental support for interdependence between the F-actin network and the NF-κB pathway with RELA translocation dynamics in PDAC.